Raras
Buscar doenças, sintomas, genes...
Doença neuromuscular
ORPHA:68381DOENÇA RARA
immune
Também conhecida comoDoenças neuromuscularesDoença muscularDoenças musculares

Qualquer doença que atrapalha o funcionamento dos músculos, seja de forma direta, afetando o próprio músculo que movemos, ou indiretamente, quando atinge os nervos ou as conexões entre os nervos e os músculos.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋
Informacoes curadas por IA — podem conter imprecisoes

Qualquer doença que atrapalha o funcionamento dos músculos, seja de forma direta, afetando o próprio músculo que movemos, ou indiretamente, quando atinge os nervos ou as conexões entre os nervos e os músculos.

Pesquisas ativas
2 ensaios
9400 total registrados no ClinicalTrials.gov
Publicações científicas
5.414 artigos
Último publicado: 2026
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
270 sintomas
💪
Músculos
256 sintomas
🦴
Ossos e articulações
181 sintomas
👁️
Olhos
126 sintomas
❤️
Coração
103 sintomas
😀
Face
98 sintomas

+ 1185 sintomas em outras categorias

Características mais comuns

Autoimunidade
Luxação congênita do joelho
Deformidades congênitas de contratura do pé
Atrofia do neurônio motor
Anormalidade da gengiva
Morfologia anormal do hipocampo
2649sintomas
Sem dados (2649)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 2649 características clínicas mais associadas, ordenadas por frequência.

AutoimunidadeAutoimmunity
Luxação congênita do joelhoCongenital knee dislocation
Deformidades congênitas de contratura do péCongenital foot contraction deformities
Atrofia do neurônio motorMotor neuron atrophy
Anormalidade da gengivaAbnormality of the gingiva

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico5.414PubMed
Últimos 10 anos200publicações
Pico2026102 papers
Linha do tempo
2026Hoje · 2026🧪 1976Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

94 genes identificados com associação a esta condição.

Curadoria gene-doença

fontes oficiais
RAPSN TRPV4 PLEKHG5
PLEKHG5 TRPV4
TUBB3Tubulin beta-3 chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:34996871, PubMed:38305685, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:34996871, PubMed:38305685, PubMed:38609661). Below the cap, alpha-beta tubulin heterodimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). TUBB3 plays a cr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, growth coneCell projection, lamellipodiumCell projection, filopodium

VIAS BIOLÓGICAS (10)
HCMV Early EventsPKR-mediated signalingGap junction assemblyAggrephagyAssembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 3A

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 3 presents as a non-progressive, autosomal dominant disorder with variable expression. Patients may be bilaterally or unilaterally affected, and their oculo-motility defects range from complete ophthalmoplegia (with the eyes fixed in a hypo- and exotropic position), to mild asymptomatic restrictions of ocular movement. Ptosis, refractive error, amblyopia, and compensatory head positions are associated with the more severe forms of the disorder. In some cases, the ocular phenotype is accompanied by additional features including developmental delay, corpus callosum agenesis, basal ganglia dysmorphism, facial weakness, polyneuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Hipotálamo
143.8 TPM
Brain Frontal Cortex BA9
123.1 TPM
Córtex cerebral
102.0 TPM
Cérebro - Hemisfério cerebelar
101.2 TPM
Cerebelo
101.0 TPM
OUTRAS DOENÇAS (4)
fibrosis of extraocular muscles, congenital, 3A, with or without extraocular involvementcomplex cortical dysplasia with other brain malformations 1congenital fibrosis of extraocular musclestubulinopathy-associated dysgyria
HGNC:20772UniProt:Q13509
TSEN2tRNA-splicing endonuclease subunit Sen2Candidate gene tested inTolerante
FUNÇÃO

Constitutes one of the two catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5'- and 3'-splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3'-cyclic phosphate and 5'-OH termini. There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2B

A disorder characterized by an abnormally small cerebellum and brainstem, and progressive microcephaly from birth combined with extrapyramidal dyskinesia. Severe chorea occurs and epilepsy is frequent. There are no signs of spinal cord anterior horn cells degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
11.4 TPM
Ovário
11.0 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
Útero
10.0 TPM
Fibroblastos
9.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 2Bpontocerebellar hypoplasia type 2
HGNC:28422UniProt:Q8NCE0
GSNGelsolinCandidate gene tested inTolerante
FUNÇÃO

Calcium-regulated, actin-modulating protein that binds to the plus (or barbed) ends of actin monomers or filaments, preventing monomer exchange (end-blocking or capping). It can promote the assembly of monomers into filaments (nucleation) as well as sever filaments already formed (PubMed:19666512). Plays a role in ciliogenesis (PubMed:20393563)

LOCALIZAÇÃO

Cytoplasm, cytoskeletonSecreted

MECANISMO DE DOENÇA

Amyloidosis, hereditary systemic 4, Finnish type

A form of hereditary systemic amyloidosis, a disorder characterized by amyloid deposition in multiple tissues resulting in a wide clinical spectrum. AMYLD4 is due to gelsolin amyloid deposition and is typically characterized by cranial neuropathy and lattice corneal dystrophy. Most patients have modest involvement of internal organs, but severe systemic disease can develop in some individuals causing peripheral polyneuropathy, amyloid cardiomyopathy, and nephrotic syndrome leading to renal failure. AMYLD4 is usually inherited in an autosomal dominant pattern. However, homozygotes with a more severe phenotype have also been reported.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
2343.5 TPM
Nervo tibial
1919.4 TPM
Artéria tibial
1624.6 TPM
Aorta
1619.7 TPM
Artéria coronária
1564.3 TPM
OUTRAS DOENÇAS (1)
Finnish type amyloidosis
HGNC:4620UniProt:P06396
AARS1Alanine--tRNA ligase, cytoplasmicCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction: alanine is first activated by ATP to form Ala-AMP and then transferred to the acceptor end of tRNA(Ala) (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:33909043). Also edits incorrectly charged tRNA(Ala) via its editing domain (PubMed:27622773, PubMed:27911835, PubMed:28493438, PubMed:29273753). In presence of high levels of lactate, also acts as a protein lactyltransferase that mediates lactylation of lysine res

LOCALIZAÇÃO

CytoplasmNucleus

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2N

An axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (6)
trichothiodystrophy 8, nonphotosensitiveleukoencephalopathy, hereditary diffuse, with spheroids 2developmental and epileptic encephalopathy, 29Charcot-Marie-Tooth disease axonal type 2N
HGNC:20UniProt:P49588
AIFM1Apoptosis-inducing factor 1, mitochondrialCandidate gene tested inAltamente restrito
FUNÇÃO

Functions both as NADH oxidoreductase and as regulator of apoptosis (PubMed:17094969, PubMed:20362274, PubMed:23217327, PubMed:33168626). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway (PubMed:20362274). Release into the cytoplasm is mediated upon binding to poly-ADP-ribose chains (By similarity). The soluble form (AIFsol) found in the nuc

LOCALIZAÇÃO

Mitochondrion intermembrane spaceMitochondrion inner membraneCytoplasmNucleusCytoplasm, perinuclear regionMitochondrionCytoplasm, cytosol

MECANISMO DE DOENÇA

Combined oxidative phosphorylation deficiency 6

A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy.

OUTRAS DOENÇAS (4)
X-linked hereditary sensory and autonomic neuropathy with hearing lossCharcot-Marie-Tooth disease X-linked recessive 4spondyloepimetaphyseal dysplasia, Bieganski typesevere X-linked mitochondrial encephalomyopathy
HGNC:8768UniProt:O95831
SPTLC2Serine palmitoyltransferase 2Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases (PubMed:19416851, PubMed:19648650, PubMed:20504773, PubMed:20920666). The SPT complex is composed of SPTLC1, SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer consisting of SPTLC1 and SPTLC2/SPTLC3 forms the catalytic core

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Sphingolipid de novo biosynthesis
MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 1C

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by prominent sensory abnormalities with a variable degree of motor and autonomic dysfunction. The neurological phenotype is often complicated by severe infections, osteomyelitis, and amputations. HSAN1C symptoms include loss of touch and vibration in the feet, dysesthesia and severe panmodal sensory loss in the upper and lower limbs, distal lower limb sensory loss with ulceration and osteomyelitis, and distal muscle weakness.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
49.9 TPM
Baço
29.7 TPM
Esôfago - Mucosa
26.9 TPM
Adipose Visceral Omentum
25.0 TPM
Tecido adiposo
24.1 TPM
OUTRAS DOENÇAS (2)
neuropathy, hereditary sensory and autonomic, type 1Chereditary sensory and autonomic neuropathy type 1
HGNC:11278UniProt:O15270
CRPPAD-ribitol-5-phosphate cytidylyltransferaseCandidate gene tested inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
NEFLNeurofilament light polypeptideCandidate gene tested inTolerante
FUNÇÃO

Neurofilaments usually contain three intermediate filament proteins: NEFL, NEFM, and NEFH which are involved in the maintenance of neuronal caliber. May additionally cooperate with the neuronal intermediate filament proteins PRPH and INA to form neuronal filamentous networks (By similarity)

LOCALIZAÇÃO

Cell projection, axonCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (6)
RAF/MAP kinase cascadeRas activation upon Ca2+ influx through NMDA receptorUnblocking of NMDA receptors, glutamate binding and activationLong-term potentiationNegative regulation of NMDA receptor-mediated neuronal transmission
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1F

A dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years).

EXPRESSÃO TECIDUAL(Tecido-específico)
Brain Frontal Cortex BA9
487.2 TPM
Córtex cerebral
328.6 TPM
Brain Anterior cingulate cortex BA24
195.3 TPM
Hipotálamo
136.9 TPM
Substância negra
100.6 TPM
OUTRAS DOENÇAS (4)
Charcot-Marie-Tooth disease type 1FCharcot-Marie-Tooth disease, dominant intermediate GCharcot-Marie-Tooth disease type 2ECharcot-Marie-Tooth disease type 2B5
HGNC:7739UniProt:P07196
ASCC1Activating signal cointegrator 1 complex subunit 1Candidate gene tested inTolerante
FUNÇÃO

Plays a role in DNA damage repair as component of the ASCC complex (PubMed:29997253). Part of the ASC-1 complex that enhances NF-kappa-B, SRF and AP1 transactivation (PubMed:12077347). In cells responding to gastrin-activated paracrine signals, it is involved in the induction of SERPINB2 expression by gastrin. May also play a role in the development of neuromuscular junction

LOCALIZAÇÃO

NucleusNucleus speckle

VIAS BIOLÓGICAS (1)
ALKBH3 mediated reversal of alkylation damage
MECANISMO DE DOENÇA

Barrett esophagus

A condition characterized by a metaplastic change in which normal esophageal squamous epithelium is replaced by a columnar and intestinal-type epithelium. Patients with Barrett esophagus have an increased risk of esophageal adenocarcinoma. The main cause of Barrett esophagus is gastroesophageal reflux. The retrograde movement of acid and bile salts from the stomach into the esophagus causes prolonged injury to the esophageal epithelium and induces chronic esophagitis, which in turn is believed to trigger the pathologic changes.

OUTRAS DOENÇAS (3)
spinal muscular atrophy with congenital bone fractures 2Barrett esophagusprenatal-onset spinal muscular atrophy with congenital bone fractures
HGNC:24268UniProt:Q8N9N2
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinCandidate gene tested inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777
TYMPThymidine phosphorylaseCandidate gene tested inTolerante
FUNÇÃO

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Pyrimidine salvagePyrimidine catabolism
MECANISMO DE DOENÇA

Mitochondrial DNA depletion syndrome 1, MNGIE type

A multisystem disease associated with mitochondrial dysfunction. It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, cachexia, peripheral neuropathy, and myopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
330.6 TPM
Pulmão
260.6 TPM
Baço
215.3 TPM
Tecido adiposo
140.0 TPM
Adipose Visceral Omentum
116.4 TPM
OUTRAS DOENÇAS (2)
mitochondrial DNA depletion syndrome 1mitochondrial neurogastrointestinal encephalomyopathy
HGNC:3148UniProt:P19971
SMN2Survival motor neuron proteinCandidate gene tested inModerado
FUNÇÃO

The SMN complex catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome, and thereby plays an important role in the splicing of cellular pre-mRNAs (PubMed:18984161, PubMed:9845364). Most spliceosomal snRNPs contain a common set of Sm proteins SNRPB, SNRPD1, SNRPD2, SNRPD3, SNRPE, SNRPF and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP (Sm core) (PubMed:18984161). In the cytosol,

LOCALIZAÇÃO

Nucleus, gemNucleus, Cajal bodyCytoplasmCytoplasmic granulePerikaryonCell projection, neuron projectionCell projection, axonCytoplasm, myofibril, sarcomere, Z line

VIAS BIOLÓGICAS (2)
snRNP AssemblySARS-CoV-2 modulates host translation machinery
MECANISMO DE DOENÇA

Spinal muscular atrophy 1

A form of spinal muscular atrophy, a group of neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical muscle weakness and atrophy. Autosomal recessive forms are classified according to the age of onset, the maximum muscular activity achieved, and survivorship. The severity of the disease is mainly determined by the copy number of SMN2, a copy gene which predominantly produces exon 7-skipped transcripts and only low amount of full-length transcripts that encode for a protein identical to SMN1. Only about 4% of SMA patients bear one SMN1 copy with an intragenic mutation. SMA1 is a severe form, with onset before 6 months of age. SMA1 patients never achieve the ability to sit.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cervix Ectocervix
4.9 TPM
Ovário
4.9 TPM
Testículo
4.5 TPM
Útero
4.4 TPM
Linfócitos
4.2 TPM
OUTRAS DOENÇAS (4)
spinal muscular atrophy, type IVspinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:11118UniProt:Q16637
ARL6IP1ADP-ribosylation factor-like protein 6-interacting protein 1Candidate gene tested inTolerante
FUNÇÃO

Positively regulates SLC1A1/EAAC1-mediated glutamate transport by increasing its affinity for glutamate in a PKC activity-dependent manner. Promotes the catalytic efficiency of SLC1A1/EAAC1 probably by reducing its interaction with ARL6IP5, a negative regulator of SLC1A1/EAAC1-mediated glutamate transport (By similarity). Plays a role in the formation and stabilization of endoplasmic reticulum tubules (PubMed:24262037). Negatively regulates apoptosis, possibly by modulating the activity of caspa

LOCALIZAÇÃO

Endomembrane systemEndoplasmic reticulum membraneEndoplasmic reticulum

MECANISMO DE DOENÇA

Spastic paraplegia 61, autosomal recessive

A complicated form of spastic paraplegia with polysensory and motor neuropathy. Spastic paraplegia is a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 61
HGNC:697UniProt:Q15041
ERLIN1Erlin-1Candidate gene tested inTolerante
FUNÇÃO

Component of the ERLIN1/ERLIN2 complex which mediates the endoplasmic reticulum-associated degradation (ERAD) of inositol 1,4,5-trisphosphate receptors (IP3Rs). Involved in regulation of cellular cholesterol homeostasis by regulation the SREBP signaling pathway (PubMed:37683630). Binds cholesterol and may promote ER retention of the SCAP-SREBF complex (PubMed:24217618) (Microbial infection) Required early in hepatitis C virus (HCV) infection to initiate RNA replication, and later in the infectio

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (3)
AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)ABC-family proteins mediated transportDefective CFTR causes cystic fibrosis
MECANISMO DE DOENÇA

Spastic paraplegia 62, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
58.3 TPM
Vagina
30.3 TPM
Fígado
28.9 TPM
Esôfago - Mucosa
25.4 TPM
Cervix Endocervix
24.5 TPM
OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 62
HGNC:16947UniProt:O75477
SGCAAlpha-sarcoglycanCandidate gene tested inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 3

An autosomal recessive degenerative myopathy characterized by progressive muscle wasting from early childhood with loss of independent ambulation by teenage years. Muscle biopsy shows necrosis, decreased immunostaining for alpha sarcoglycan, and adhalin deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
227.0 TPM
Aorta
223.0 TPM
Artéria tibial
162.2 TPM
Artéria coronária
146.7 TPM
Esôfago - Junção
94.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophyautosomal recessive limb-girdle muscular dystrophy type 2D
HGNC:10805UniProt:Q16586
CPT1CPalmitoyl thioesterase CPT1CCandidate gene tested inTolerante
FUNÇÃO

Palmitoyl thioesterase specifically expressed in the endoplasmic reticulum of neurons. Modulates the trafficking of the glutamate receptor, AMPAR, to plasma membrane through depalmitoylation of GRIA1 (PubMed:30135643). Also regulates AMPR trafficking through the regulation of SACM1L phosphatidylinositol-3-phosphatase activity by interaction in a malonyl-CoA dependent manner (By similarity). Binds malonyl-CoA and couples malonyl-CoA to ceramide levels, necessary for proper spine maturation and co

LOCALIZAÇÃO

Cell projection, dendriteCell projection, axonEndoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Carnitine shuttle
MECANISMO DE DOENÇA

Spastic paraplegia 73, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 73
HGNC:18540UniProt:Q8TCG5
SPARTSpartinCandidate gene tested inTolerante
FUNÇÃO

Lipophagy receptor that plays an important role in lipid droplet (LD) turnover in motor neurons (PubMed:37443287). Localizes to LDs and interacts with components of the autophagy machinery, such as MAP1LC3A/C proteins to deliver LDs to autophagosomes for degradation via lipophagy (PubMed:37443287). Lipid transfer protein required for lipid droplet degradation, including by lipophagy (PubMed:38190532). Can bind and transfer all lipid species found in lipid droplets, from phospholipids to triglyce

LOCALIZAÇÃO

CytoplasmMidbodyLipid droplet

MECANISMO DE DOENÇA

Spastic paraplegia 20, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG20 is characterized by dysarthria, distal amyotrophy, mild developmental delay and short stature.

OUTRAS DOENÇAS (1)
Troyer syndrome
HGNC:18514UniProt:Q8N0X7
MTTPMicrosomal triglyceride transfer protein large subunitCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the transport of triglyceride, cholesteryl ester, and phospholipid between phospholipid surfaces (PubMed:15897609, PubMed:16478722, PubMed:22236406, PubMed:23475612, PubMed:25108285, PubMed:26224785, PubMed:8876250, PubMed:8939939). Required for the assembly and secretion of plasma lipoproteins that contain apolipoprotein B (PubMed:16478722, PubMed:23475612, PubMed:26224785, PubMed:8876250, PubMed:8939939). May be involved in regulating cholesteryl ester biosynthesis in cells that prod

LOCALIZAÇÃO

Endoplasmic reticulumGolgi apparatus

VIAS BIOLÓGICAS (3)
VLDL assemblyChylomicron assemblyLDL remodeling
MECANISMO DE DOENÇA

Abetalipoproteinemia

An autosomal recessive disorder of lipoprotein metabolism. Affected individuals produce virtually no circulating apolipoprotein B-containing lipoproteins (chylomicrons, VLDL, LDL, lipoprotein(A)). Malabsorption of the antioxidant vitamin E occurs, leading to spinocerebellar and retinal degeneration.

EXPRESSÃO TECIDUAL(Tecido-específico)
Fígado
31.1 TPM
Intestino delgado
24.7 TPM
Testículo
7.1 TPM
Ovário
1.8 TPM
Linfócitos
1.2 TPM
OUTRAS DOENÇAS (1)
abetalipoproteinemia
HGNC:7467UniProt:P55157
DSTYKDual serine/threonine and tyrosine protein kinaseCandidate gene tested inAltamente restrito
FUNÇÃO

Acts as a positive regulator of ERK phosphorylation downstream of fibroblast growth factor-receptor activation (PubMed:23862974, PubMed:28157540). Involved in the regulation of both caspase-dependent apoptosis and caspase-independent cell death (PubMed:15178406). In the skin, it plays a predominant role in suppressing caspase-dependent apoptosis in response to UV stress in a range of dermal cell types (PubMed:28157540)

LOCALIZAÇÃO

CytoplasmCell membraneApical cell membraneBasolateral cell membraneCell junction

MECANISMO DE DOENÇA

Congenital anomalies of the kidney and urinary tract 1

A disorder encompassing a broad spectrum of renal and urinary tract malformations that include renal agenesis, kidney hypodysplasia, multicystic kidney dysplasia, duplex collecting system, posterior urethral valves and ureter abnormalities. Congenital anomalies of kidney and urinary tract are the commonest cause of chronic kidney disease in children.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
33.1 TPM
Cerebelo
25.4 TPM
Útero
16.7 TPM
Brain Frontal Cortex BA9
15.5 TPM
Ovário
14.8 TPM
OUTRAS DOENÇAS (3)
congenital anomalies of kidney and urinary tract 1hereditary spastic paraplegia 23renal agenesis, unilateral
HGNC:29043UniProt:Q6XUX3
MMACHCCyanocobalamin reductase / alkylcobalamin dealkylaseCandidate gene tested inTolerante
FUNÇÃO

Cobalamin (vitamin B12) cytosolic chaperone that catalyzes the reductive decyanation of cyanocob(III)alamin (cyanocobalamin, CNCbl) to yield cob(II)alamin and cyanide, using FAD or FMN as cofactors and NADPH as cosubstrate (PubMed:18779575, PubMed:19700356, PubMed:21697092, PubMed:25809485). Cyanocobalamin constitutes the inactive form of vitamin B12 introduced from the diet, and is converted into the active cofactors methylcobalamin (MeCbl) involved in methionine biosynthesis, and 5'-deoxyadeno

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (2)
Cobalamin (Cbl) metabolismDefective MMADHC causes MMAHCD
MECANISMO DE DOENÇA

Methylmalonic aciduria and homocystinuria, cblC type

An autosomal recessive disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, hematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings. Although considered a disease of infancy or childhood, some individuals develop symptoms in adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
9.1 TPM
Testículo
7.5 TPM
Fibroblastos
6.7 TPM
Linfócitos
5.8 TPM
Glândula adrenal
4.4 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:24525UniProt:Q9Y4U1
PDHBPyruvate dehydrogenase E1 component subunit beta, mitochondrialCandidate gene tested inRestrito
FUNÇÃO

Together with PDHA1 forms the heterotetrameric E1 subunit of the pyruvate dehydrogenase (PDH) complex (PubMed:17474719, PubMed:19081061). The PDH complex catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3) (P

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (4)
Signaling by Retinoic AcidRegulation of pyruvate dehydrogenase (PDH) complexPDH complex synthesizes acetyl-CoA from PYRMitochondrial protein degradation
MECANISMO DE DOENÇA

Pyruvate dehydrogenase E1-beta deficiency

An enzymatic defect causing primary lactic acidosis in children. It is associated with a broad clinical spectrum ranging from fatal lactic acidosis in the newborn to chronic neurologic dysfunction with structural abnormalities in the central nervous system without systemic acidosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
122.9 TPM
Esôfago - Muscular
118.3 TPM
Fibroblastos
115.0 TPM
Coração - Ventrículo esquerdo
110.6 TPM
Artéria tibial
106.5 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E1-beta deficiency
HGNC:8808UniProt:P11177
PDP1Polyisoprenoid diphosphate/phosphate phosphohydrolase PLPP6Candidate gene tested inRestrito
FUNÇÃO

Magnesium-independent polyisoprenoid diphosphatase that catalyzes the sequential dephosphorylation of presqualene, farnesyl, geranyl and geranylgeranyl diphosphates (PubMed:16464866, PubMed:19220020, PubMed:20110354). Functions in the innate immune response through the dephosphorylation of presqualene diphosphate which acts as a potent inhibitor of the signaling pathways contributing to polymorphonuclear neutrophils activation (PubMed:16464866, PubMed:23568778). May regulate the biosynthesis of

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus envelopeNucleus inner membrane

VIAS BIOLÓGICAS (1)
Regulation of pyruvate dehydrogenase (PDH) complex
VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Brain Frontal Cortex BA9
51.5 TPM
Glândula adrenal
34.6 TPM
Testículo
29.8 TPM
Córtex cerebral
28.2 TPM
Fibroblastos
20.0 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase phosphatase deficiency
HGNC:9279UniProt:Q8IY26
DLATDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

The pyruvate dehydrogenase (PDH) complex, catalyzes the overall conversion of pyruvate to acetyl-CoA and CO(2), and thereby links cytoplasmic glycolysis and the mitochondrial tricarboxylic acid (TCA) cycle (Probable). It contains multiple copies of three enzymatic components: pyruvate dehydrogenase (E1), dihydrolipoamide acetyltransferase (E2) and dihydrolipoamide dehydrogenase (E3); (Probable). Within this complex, the catalytic function of this enzyme is to accept, and to transfer to coenzyme

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (3)
PDH complex synthesizes acetyl-CoA from PYRProtein lipoylationRegulation of pyruvate dehydrogenase (PDH) complex
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
38.4 TPM
Linfócitos
37.6 TPM
Coração - Ventrículo esquerdo
36.5 TPM
Fibroblastos
31.1 TPM
Coração - Átrio
26.7 TPM
OUTRAS DOENÇAS (1)
pyruvate dehydrogenase E2 deficiency
HGNC:2896UniProt:P10515
SCN4ASodium channel protein type 4 subunit alphaCandidate gene tested inTolerante
FUNÇÃO

Pore-forming subunit of Nav1.4, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes. Navs, also called VGSCs (voltage-gated sodium channels) or VDSCs (voltage-dependent sodium channels), operate by switching between closed and open conformations depending on the voltage difference across the membrane. In the open conformation they allow Na(+) ions to selectively pass through the pore, along their electrochemical gradient.

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Interaction between L1 and AnkyrinsPhase 0 - rapid depolarisation
MECANISMO DE DOENÇA

Paramyotonia congenita

An autosomal dominant channelopathy characterized by myotonia, increased by exposure to cold, intermittent flaccid paresis, not necessarily dependent on cold or myotonia, lability of serum potassium, non-progressive nature and lack of atrophy or hypertrophy of muscles. In some patients, myotonia is not increased by cold exposure (paramyotonia without cold paralysis). Patients may have a combination phenotype of PMC and HYPP.

EXPRESSÃO TECIDUAL(Tecido-específico)
Músculo esquelético
80.7 TPM
Adipose Visceral Omentum
29.9 TPM
Mama
21.0 TPM
Tecido adiposo
18.1 TPM
Tireoide
10.4 TPM
OUTRAS DOENÇAS (12)
potassium-aggravated myotoniacongenital myopathy 22A, classiccongenital myopathy 22B, severe fetalhyperkalemic periodic paralysis
HGNC:10591UniProt:P35499
EXOSC9Exosome complex component RRP45Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolusNucleus, nucleoplasm

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1D

An autosomal recessive neurologic disorder with onset at birth or in infancy, and characterized by progressive axonal motor neuronopathy, severe generalized hypotonia, respiratory insufficiency, and cerebellar atrophy. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
43.9 TPM
Testículo
34.6 TPM
Fibroblastos
34.4 TPM
Nervo tibial
24.9 TPM
Cérebro - Hemisfério cerebelar
23.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Dpontocerebellar hypoplasia type 1
HGNC:9137UniProt:Q06265
NAIPBaculoviral IAP repeat-containing protein 1Candidate gene tested inTolerante
FUNÇÃO

Anti-apoptotic protein which acts by inhibiting the activities of CASP3, CASP7 and CASP9. Can inhibit the autocleavage of pro-CASP9 and cleavage of pro-CASP3 by CASP9. Capable of inhibiting CASP9 autoproteolysis at 'Asp-315' and decreasing the rate of auto proteolysis at 'Asp-330'. Acts as a mediator of neuronal survival in pathological conditions. Prevents motor-neuron apoptosis induced by a variety of signals. Possible role in the prevention of spinal muscular atrophy that seems to be caused b

LOCALIZAÇÃO

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
5.8 TPM
Baço
3.8 TPM
Pulmão
1.3 TPM
Testículo
1.0 TPM
Fallopian Tube
0.9 TPM
OUTRAS DOENÇAS (3)
spinal muscular atrophy, type 1spinal muscular atrophy, type IIspinal muscular atrophy, type III
HGNC:7634UniProt:Q13075
PNKPBifunctional polynucleotide phosphatase/kinaseCandidate gene tested inTolerante
FUNÇÃO

Plays a key role in the repair of DNA damage, functioning as part of both the non-homologous end-joining (NHEJ) and base excision repair (BER) pathways (PubMed:10446192, PubMed:10446193, PubMed:15385968, PubMed:20852255, PubMed:28453785). Through its two catalytic activities, PNK ensures that DNA termini are compatible with extension and ligation by either removing 3'-phosphates from, or by phosphorylating 5'-hydroxyl groups on, the ribose sugar of the DNA backbone (PubMed:10446192, PubMed:10446

LOCALIZAÇÃO

NucleusChromosome

VIAS BIOLÓGICAS (1)
APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
MECANISMO DE DOENÇA

Microcephaly, seizures, and developmental delay

An autosomal recessive neurodevelopmental disorder characterized by infantile-onset seizures, microcephaly, severe intellectual disability and delayed motor milestones with absent speech or only achieving a few words. Most patients also have behavioral problems with hyperactivity. Microcephaly is progressive and without neuronal migration or structural abnormalities, consistent with primary microcephaly.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
66.8 TPM
Tireoide
63.9 TPM
Baço
59.2 TPM
Glândula adrenal
55.9 TPM
Cervix Endocervix
51.8 TPM
OUTRAS DOENÇAS (4)
microcephaly, seizures, and developmental delayataxia - oculomotor apraxia type 4Charcot-Marie-Tooth disease type 2B2early-infantile DEE
HGNC:9154UniProt:Q96T60
GPT2Alanine aminotransferase 2Candidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate

LOCALIZAÇÃO

VIAS BIOLÓGICAS (1)
Alanine metabolism
MECANISMO DE DOENÇA

Neurodevelopmental disorder with spastic paraplegia and microcephaly

An autosomal recessive syndrome characterized by severe psychomotor developmental delay, dysarthria, walking difficulties, moderately to severely impaired intellectual development, poor or absent speech, and progressive microcephaly.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
93.0 TPM
Estômago
87.0 TPM
Fígado
65.7 TPM
Glândula salivar
61.2 TPM
Skin Not Sun Exposed Suprapubic
59.9 TPM
OUTRAS DOENÇAS (1)
glutamate pyruvate transaminase 2 deficiency
HGNC:18062UniProt:Q8TD30
SETXHelicase senataxinCandidate gene tested inAltamente restrito
FUNÇÃO

ATP-dependent 5'->3' DNA/RNA helicase that preferentially unwinds RNA substrates over DNA, playing a crucial role in resolving R-loops and promoting transcription termination (PubMed:36864660). Plays a role in transcription regulation by its ability to modulate RNA Polymerase II (Pol II) binding to chromatin and through its interaction with proteins involved in transcription (PubMed:19515850, PubMed:21700224). Contributes to the mRNA splicing efficiency and splice site selection (PubMed:19515850

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmNucleus, nucleolusCytoplasmChromosomeChromosome, telomereCell projection, axonCell projection, growth cone

MECANISMO DE DOENÇA

Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2

A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. SCAN2 is an autosomal recessive form associated with peripheral neuropathy and elevated serum alpha-fetoprotein, immunoglobulins and, less commonly, creatine kinase levels. Some SCAN2 patients manifest oculomotor apraxia.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
50.4 TPM
Linfócitos
39.4 TPM
Tireoide
36.1 TPM
Baço
32.8 TPM
Pulmão
25.9 TPM
OUTRAS DOENÇAS (2)
spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2amyotrophic lateral sclerosis type 4
HGNC:445UniProt:Q7Z333
VRK1Serine/threonine-protein kinase VRK1Candidate gene tested inTolerante
FUNÇÃO

Serine/threonine kinase involved in the regulation of key cellular processes including the cell cycle, nuclear condensation, transcription regulation, and DNA damage response (PubMed:14645249, PubMed:18617507, PubMed:19103756, PubMed:33076429). Controls chromatin organization and remodeling by mediating phosphorylation of histone H3 on 'Thr-4' and histone H2AX (H2aXT4ph) (PubMed:31527692, PubMed:37179361). It also phosphorylates KAT5 in response to DNA damage, promoting KAT5 association with chr

LOCALIZAÇÃO

NucleusCytoplasmNucleus, Cajal body

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1A

A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH1A is an autosomal recessive form characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth, gliosis and spinal cord anterior horn cells degeneration resembling infantile spinal muscular atrophy. Additional features include muscle hypotonia, congenital contractures and respiratory insufficiency that is evident at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.6 TPM
Testículo
41.3 TPM
Baço
13.9 TPM
Fibroblastos
12.9 TPM
Fallopian Tube
9.9 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal recessive 10pontocerebellar hypoplasia type 1Apontocerebellar hypoplasia type 1microcephaly-complex motor and sensory axonal neuropathy syndrome
HGNC:12718UniProt:Q99986
EXOSC3Exosome complex component RRP40Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleus, nucleolusNucleus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1B

A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.1 TPM
Testículo
28.1 TPM
Fibroblastos
21.2 TPM
Cervix Endocervix
16.4 TPM
Ovário
15.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 1Bpontocerebellar hypoplasia type 1
HGNC:17944UniProt:Q9NQT5
EXOSC8Exosome complex component RRP43Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1C

A severe autosomal recessive neurodegenerative disease characterized by cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system, and spinal motor neuron disease. Affected individuals manifest failure to thrive, severe muscle weakness, spasticity and psychomotor retardation. Vision and hearing are impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.2 TPM
Testículo
43.8 TPM
Ovário
40.4 TPM
Cervix Endocervix
38.1 TPM
Fallopian Tube
37.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Cpontocerebellar hypoplasia type 1
HGNC:17035UniProt:Q96B26
TRAPPC11Trafficking protein particle complex subunit 11Candidate gene tested inTolerante
FUNÇÃO

Involved in endoplasmic reticulum to Golgi apparatus trafficking at a very early stage

LOCALIZAÇÃO

Golgi apparatusGolgi apparatus, cis-Golgi network

VIAS BIOLÓGICAS (1)
RAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 18

A form of limb-girdle muscular dystrophy characterized by proximal muscle weakness with childhood onset, resulting in gait abnormalities and scapular winging. Serum creatine kinase is increased. A subset of patients may show a hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
33.7 TPM
Cérebro - Hemisfério cerebelar
31.5 TPM
Linfócitos
30.9 TPM
Nervo tibial
29.6 TPM
Cerebelo
29.4 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type R18intellectual disability-hyperkinetic movement-truncal ataxia syndrometriple-A syndrome
HGNC:25751UniProt:Q7Z392
OATOrnithine aminotransferase, mitochondrialCandidate gene tested inTolerante
FUNÇÃO

Catalyzes the reversible interconversion of L-ornithine and 2-oxoglutarate to L-glutamate semialdehyde and L-glutamate

LOCALIZAÇÃO

Mitochondrion matrix

VIAS BIOLÓGICAS (1)
Glutamate and glutamine metabolism
MECANISMO DE DOENÇA

Hyperornithinemia with gyrate atrophy of choroid and retina

A disorder clinically characterized by a triad of progressive chorioretinal degeneration, early cataract formation, and type II muscle fiber atrophy. Characteristic chorioretinal atrophy with progressive constriction of the visual fields leads to blindness at the latest during the sixth decade of life. Patients generally have normal intelligence.

EXPRESSÃO TECIDUAL(Ubíquo)
Intestino delgado
165.3 TPM
Fibroblastos
139.5 TPM
Aorta
118.9 TPM
Artéria tibial
116.9 TPM
Cervix Endocervix
110.6 TPM
OUTRAS DOENÇAS (1)
ornithine aminotransferase deficiency
HGNC:8091UniProt:P04181
MT-ATP6ATP synthase F(0) complex subunit aCandidate gene tested inDesconhecido
FUNÇÃO

Subunit a, of the mitochondrial membrane ATP synthase complex (F(1)F(0) ATP synthase or Complex V) that produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain (Probable). ATP synthase complex consist of a soluble F(1) head domain - the catalytic core - and a membrane F(1) domain - the membrane proton channel (PubMed:37244256). These two domains are linked by a central stalk rotating inside the F(1

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (4)
Mitochondrial translation terminationFormation of ATP by chemiosmotic couplingCristae formationMitochondrial protein degradation
MECANISMO DE DOENÇA

Neuropathy, ataxia, and retinitis pigmentosa

A syndrome characterized by variable combination of developmental delay, psychomotor retardation, hearing loss, optic atrophy and retinitis pigmentosa, dementia, seizures, ataxia, proximal neurogenic muscle weakness, and sensory neuropathy.

OUTRAS DOENÇAS (8)
mitochondrial diseasematernally-inherited Leigh syndromefamilial infantile bilateral striatal necrosismitochondrial proton-transporting ATP synthase complex deficiency
HGNC:7414UniProt:P00846
MT-TL1Candidate gene tested inDesconhecido
LOCALIZAÇÃO

VIAS BIOLÓGICAS (3)
G alpha (i) signalling eventsFormyl peptide receptors bind formyl peptides and many other ligandsG alpha (q) signalling events
OUTRAS DOENÇAS (7)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeMERRF syndrome
HGNC:7490
MT-ND4NADH-ubiquinone oxidoreductase chain 4Candidate gene tested inDesconhecido
FUNÇÃO

Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) which catalyzes electron transfer from NADH through the respiratory chain, using ubiquinone as an electron acceptor (PubMed:15250827, PubMed:8344246, PubMed:8644732). Essential for the catalytic activity and assembly of complex I (PubMed:15250827, PubMed:8344246, PubMed:8644732)

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (3)
Respiratory electron transportComplex I biogenesisMitochondrial translation termination
MECANISMO DE DOENÇA

Leber hereditary optic neuropathy

A maternally inherited form of Leber hereditary optic neuropathy, a mitochondrial disease resulting in bilateral painless loss of central vision due to selective degeneration of the retinal ganglion cells and their axons. The disorder shows incomplete penetrance and male predominance. Cardiac conduction defects and neurological defects have also been described in some LHON patients. LHON results from primary mitochondrial DNA mutations affecting the respiratory chain complexes.

OUTRAS DOENÇAS (6)
mitochondrial diseasematernally-inherited Leigh syndromeMELAS syndromeLeber plus disease
HGNC:7459UniProt:P03905
ALS2AlsinCandidate gene tested inTolerante
FUNÇÃO

May act as a GTPase regulator. Controls survival and growth of spinal motoneurons (By similarity)

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
RAC1 GTPase cycleRAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 2

A neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord, resulting in fatal paralysis. Sensory abnormalities are absent. The pathologic hallmarks of the disease include pallor of the corticospinal tract due to loss of motor neurons, presence of ubiquitin-positive inclusions within surviving motor neurons, and deposition of pathologic aggregates. The etiology of amyotrophic lateral sclerosis is likely to be multifactorial, involving both genetic and environmental factors. The disease is inherited in 5-10% of the cases.

OUTRAS DOENÇAS (4)
infantile-onset ascending hereditary spastic paralysisjuvenile primary lateral sclerosisamyotrophic lateral sclerosis type 2, juvenilejuvenile amyotrophic lateral sclerosis
HGNC:443UniProt:Q96Q42
ALDH18A1Delta-1-pyrroline-5-carboxylate synthaseCandidate gene tested inTolerante
FUNÇÃO

Bifunctional enzyme that converts glutamate to glutamate 5-semialdehyde, an intermediate in the biosynthesis of proline, ornithine and arginine

LOCALIZAÇÃO

MitochondrionMitochondrion matrix

VIAS BIOLÓGICAS (1)
Mitochondrial protein degradation
MECANISMO DE DOENÇA

Cutis laxa, autosomal recessive, 3A

A syndrome characterized by facial dysmorphism with a progeroid appearance, large and late-closing fontanel, cutis laxa, joint hyperlaxity, athetoid movements and hyperreflexia, pre- and postnatal growth retardation, intellectual deficit, developmental delay, and ophthalmologic abnormalities.

OUTRAS DOENÇAS (6)
hereditary spastic paraplegia 9Aautosomal recessive complex spastic paraplegia type 9Bcutis laxa, autosomal dominant 3ALDH18A1-related de Barsy syndrome
HGNC:9722UniProt:P54886
CAPN3Calpain-3Candidate gene tested inTolerante
FUNÇÃO

Calcium-regulated non-lysosomal thiol-protease. Proteolytically cleaves CTBP1 at 'His-409'. Mediates, with UTP25, the proteasome-independent degradation of p53/TP53 (PubMed:23357851, PubMed:27657329)

LOCALIZAÇÃO

CytoplasmNucleus, nucleolus

VIAS BIOLÓGICAS (1)
Degradation of the extracellular matrix
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 1

An autosomal recessive degenerative myopathy characterized by progressive symmetrical atrophy and weakness of the proximal limb muscles and elevated serum creatine kinase. The symptoms usually begin during the first two decades of life, and the disease gradually worsens, often resulting in loss of walking ability 10 or 20 years after onset.

OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Amuscular dystrophy, limb-girdle, autosomal dominant 4autosomal recessive limb-girdle muscular dystrophy
HGNC:1480UniProt:P20807
COL6A2Collagen alpha-2(VI) chainCandidate gene tested inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixMembrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1B

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (6)
Ullrich congenital muscular dystrophy 1BmyosclerosisBethlem myopathy 1Bintermediate collagen VI-related muscular dystrophy
HGNC:2212UniProt:P12110
ATP1A1Sodium/potassium-transporting ATPase subunit alpha-1Candidate gene tested inAltamente restrito
FUNÇÃO

This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients (PubMed:29499166, PubMed:30388404). Could also be part of an osmosensory signaling pathway that senses body-fluid sodium levels and controls salt intake behavior as well as voluntary

LOCALIZAÇÃO

Cell membraneBasolateral cell membraneCell membrane, sarcolemmaCell projection, axonMelanosome

VIAS BIOLÓGICAS (3)
Ion homeostasisIon transport by P-type ATPasesPotential therapeutics for SARS
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2DD

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (2)
Charcot-Marie-tooth disease, axonal, type 2DDhypomagnesemia, seizures, and intellectual disability 2
HGNC:799UniProt:P05023
DGAT2Diacylglycerol O-acyltransferase 2Candidate gene tested inTolerante
FUNÇÃO

Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides (PubMed:27184406). Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Also functions as an acyl-CoA retinol acyltransferase (ARAT)

LOCALIZAÇÃO

Endoplasmic reticulum membraneLipid dropletCytoplasm, perinuclear region

VIAS BIOLÓGICAS (3)
Acyl chain remodeling of DAG and TAGMLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosisTriglyceride biosynthesis
EXPRESSÃO TECIDUAL(Ubíquo)
Skin Sun Exposed Lower leg
195.8 TPM
Skin Not Sun Exposed Suprapubic
161.5 TPM
Adipose Visceral Omentum
126.7 TPM
Sangue
111.6 TPM
Tecido adiposo
108.9 TPM
OUTRAS DOENÇAS (1)
autosomal dominant charcot-marie-tooth disease type 2 due to DGAT2 mutation
HGNC:16940UniProt:Q96PD7
DMPKMyotonin-protein kinaseCandidate gene tested inTolerante
FUNÇÃO

Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus outer membraneMitochondrion outer membraneSarcoplasmic reticulum membraneCell membraneCytoplasm, cytosolMitochondrion membrane

VIAS BIOLÓGICAS (1)
Ion homeostasis
MECANISMO DE DOENÇA

Dystrophia myotonica 1

A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Junção
258.6 TPM
Esôfago - Muscular
241.8 TPM
Artéria tibial
229.7 TPM
Aorta
207.1 TPM
Cólon sigmoide
195.1 TPM
OUTRAS DOENÇAS (6)
myotonic dystrophy type 1adult-onset Steinert myotonic dystrophylate-onset Steinert myotonic dystrophycongenital-onset Steinert myotonic dystrophy
HGNC:2933UniProt:Q09013
LARGE1Xylosyl- and glucuronyltransferase LARGE1Candidate gene tested inTolerante
FUNÇÃO

Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity (PubMed:15661757, PubMed:15752776, PubMed:21987822, PubMed:22223806, PubMed:23125099, PubMed:25279697, PubMed:25279699). Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure initiated

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B6

A congenital muscular dystrophy associated with profound intellectual disability, white matter changes and structural brain abnormalities. Skeletal muscle biopsies show reduced immunolabeling of alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
22.7 TPM
Útero
20.5 TPM
Coração - Ventrículo esquerdo
17.8 TPM
Fallopian Tube
16.4 TPM
Cervix Ectocervix
15.9 TPM
OUTRAS DOENÇAS (5)
muscular dystrophy-dystroglycanopathy type B6muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A6muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:6511UniProt:O95461
UBAP1Ubiquitin-associated protein 1Candidate gene tested inAltamente restrito
FUNÇÃO

Component of the ESCRT-I complex, a regulator of vesicular trafficking process (PubMed:21757351, PubMed:22405001, PubMed:31203368). Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs) (PubMed:21757351, PubMed:22405001). Plays a role in the proteasomal degradation of ubiquitinated cell-surface proteins, such as EGFR and BST2 (PubMed:22405001, PubMed:24284069, PubMed:31203368)

LOCALIZAÇÃO

Cytoplasm, cytosolEndosome

VIAS BIOLÓGICAS (5)
Late endosomal microautophagyHCMV Late EventsMembrane binding and targetting of GAG proteinsBudding and maturation of HIV virionEndosomal Sorting Complex Required For Transport (ESCRT)
MECANISMO DE DOENÇA

Spastic paraplegia 80, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
123.8 TPM
Esôfago - Mucosa
98.7 TPM
Cervix Ectocervix
97.6 TPM
Testículo
92.6 TPM
Artéria tibial
89.4 TPM
OUTRAS DOENÇAS (2)
spastic paraplegia 80, autosomal dominanthereditary spastic paraplegia 12
HGNC:12461UniProt:Q9NZ09
FA2HFatty acid 2-hydroxylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the hydroxylation of free fatty acids at the C-2 position to produce 2-hydroxy fatty acids, which are building blocks of sphingolipids and glycosphingolipids common in neural tissue and epidermis (PubMed:15337768, PubMed:15863841, PubMed:17355976, PubMed:22517924). FA2H is stereospecific for the production of (R)-2-hydroxy fatty acids (PubMed:22517924). Plays an essential role in the synthesis of galactosphingolipids of the myelin sheath (By similarity). Responsible for the synthesis o

LOCALIZAÇÃO

Endoplasmic reticulum membraneMicrosome membrane

VIAS BIOLÓGICAS (1)
Sphingolipid de novo biosynthesis
MECANISMO DE DOENÇA

Spastic paraplegia 35, autosomal recessive, with or without neurodegeneration

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG35 is a complicated form characterized by childhood onset of gait difficulties. It has a rapid progression and many patients become wheelchair-bound as young adults. Patients manifest cognitive decline associated with leukodystrophy. Other variable neurologic features, such as dystonia, optic atrophy, and seizures may also occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
209.6 TPM
Nervo tibial
76.1 TPM
Substância negra
42.8 TPM
Hipocampo
35.9 TPM
Estômago
35.7 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 35fatty acid hydroxylase-associated neurodegeneration
HGNC:21197UniProt:Q7L5A8
REEP1Receptor expression-enhancing protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for endoplasmic reticulum (ER) network formation, shaping and remodeling; it links ER tubules to the cytoskeleton. May also enhance the cell surface expression of odorant receptors (PubMed:20200447). May play a role in long-term axonal maintenance (PubMed:24478229)

LOCALIZAÇÃO

MembraneMitochondrion membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
Expression and translocation of olfactory receptors
MECANISMO DE DOENÇA

Spastic paraplegia 31, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
67.0 TPM
Cólon sigmoide
61.1 TPM
Esôfago - Muscular
51.8 TPM
Esôfago - Junção
44.2 TPM
Artéria tibial
35.6 TPM
OUTRAS DOENÇAS (4)
hereditary spastic paraplegia 31spinal muscular atrophy, distal, autosomal recessive, 6neuronopathy, distal hereditary motor, type 5Bneuronopathy, distal hereditary motor, type 5
HGNC:25786UniProt:Q9H902
PEX5Peroxisomal targeting signal 1 receptorDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor that mediates peroxisomal import of proteins containing a C-terminal PTS1-type tripeptide peroxisomal targeting signal (SKL-type) (PubMed:11101887, PubMed:11336669, PubMed:12456682, PubMed:16314507, PubMed:17157249, PubMed:17428317, PubMed:21976670, PubMed:26344566, PubMed:7706321, PubMed:7719337, PubMed:7790377). Binds to cargo proteins containing a PTS1 peroxisomal targeting signal in the cytosol, and translocates them into the peroxisome matrix by passing through the PEX13-PEX14 dock

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome matrix

VIAS BIOLÓGICAS (1)
Pexophagy
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder 2A

A fatal peroxisome biogenesis disorder belonging to the Zellweger disease spectrum and characterized clinically by severe neurologic dysfunction with profound psychomotor retardation, severe hypotonia and neonatal seizures, craniofacial abnormalities, liver dysfunction, and biochemically by the absence of peroxisomes. Additional features include cardiovascular and skeletal defects, renal cysts, ocular abnormalities, and hearing impairment. Most severely affected individuals with the classic form of the disease (classic Zellweger syndrome) die within the first year of life.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
77.7 TPM
Cerebelo
49.0 TPM
Cérebro - Hemisfério cerebelar
48.3 TPM
Pituitária
46.8 TPM
Nervo tibial
44.2 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 2Brhizomelic chondrodysplasia punctata type 5peroxisome biogenesis disorder 2A (Zellweger)Zellweger spectrum disorders
HGNC:9719UniProt:P50542
NOTCH2NLCNotch homolog 2 N-terminal-like protein CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Human-specific protein that promotes neural progenitor proliferation and evolutionary expansion of the brain neocortex by regulating the Notch signaling pathway (PubMed:29561261, PubMed:29856954, PubMed:29856955). Able to promote neural progenitor self-renewal, possibly by down-regulating neuronal differentiation genes, thereby delaying the differentiation of neuronal progenitors and leading to an overall final increase in neuronal production (PubMed:29856954). Acts by enhancing the Notch signal

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Expression of NOTCH2NL genesNOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Neuronal intranuclear inclusion disease

An autosomal dominant, slowly progressive, neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in the central and peripheral nervous system, and also in the visceral organs. Clinical manifestations are variable and include pyramidal and extrapyramidal symptoms, cerebellar ataxia, cognitive decline and dementia, peripheral neuropathy, and autonomic dysfunction.

INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
oculopharyngodistal myopathy 3tremor, hereditary essential, 6neuronal intranuclear inclusion diseaseoculopharyngodistal myopathy
HGNC:53924UniProt:P0DPK4
TECPR2Tectonin beta-propeller repeat-containing protein 2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Probably plays a role as positive regulator of autophagy

LOCALIZAÇÃO

MECANISMO DE DOENÇA

Neuropathy, hereditary sensory and autonomic, 9, with developmental delay

A form of hereditary sensory and autonomic neuropathy, a genetically and clinically heterogeneous group of disorders characterized by degeneration of dorsal root and autonomic ganglion cells, and by sensory and/or autonomic abnormalities. HSAN9 is characterized by global developmental delay and intellectual disability, axial and appendicular hypotonia, dysarthria, and an abnormal gait that is often described as ataxic. Other features may include peripheral neuropathy, hyporeflexia, and autonomic dysfunction. Affected individuals also have dysmorphic features, thin corpus callosum on brain imaging, and episodes of central apnea, which may be fatal.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
25.5 TPM
Esôfago - Muscular
20.6 TPM
Sangue
19.8 TPM
Esôfago - Junção
19.7 TPM
Cerebelo
19.4 TPM
OUTRAS DOENÇAS (1)
hereditary spastic paraplegia 49
HGNC:19957UniProt:O15040
SLC25A46Mitochondrial outer membrane protein SLC25A46Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transmembrane protein of the mitochondrial outer membrane that controls mitochondrial organization (PubMed:26168012, PubMed:27390132, PubMed:27543974). May regulate the assembly of the MICOS (mitochondrial contact site and cristae organizing system) complex which is essential to the biogenesis and dynamics of mitochondrial cristae, the inwards folds of the inner mitochondrial membrane (PubMed:27390132). Through its interaction with the EMC (endoplasmic reticulum membrane protein complex), could

LOCALIZAÇÃO

Mitochondrion outer membrane

MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6B, with optic atrophy

An autosomal recessive neurologic disorder characterized by early-onset optic atrophy, progressive visual loss, and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease, with variable age at onset and severity. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.0 TPM
Cérebro - Hemisfério cerebelar
31.7 TPM
Fibroblastos
27.1 TPM
Cerebelo
25.2 TPM
Nervo tibial
21.7 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
neuropathy, hereditary motor and sensory, type 6Bpontocerebellar hypoplasia, type 1Epontocerebellar hypoplasia type 1hereditary motor and sensory neuropathy type 6
HGNC:25198UniProt:Q96AG3
IGHMBP2DNA-binding protein SMUBP-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

5' to 3' helicase that unwinds RNA and DNA duplexes in an ATP-dependent reaction (PubMed:19158098, PubMed:22999958, PubMed:30218034). Specific to 5'-phosphorylated single-stranded guanine-rich sequences (PubMed:22999958, PubMed:8349627). May play a role in RNA metabolism, ribosome biogenesis or initiation of translation (PubMed:19158098, PubMed:19299493). May play a role in regulation of transcription (By similarity). Interacts with tRNA-Tyr (PubMed:19299493)

LOCALIZAÇÃO

NucleusCytoplasmCell projection, axon

MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal recessive 1

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
48.4 TPM
Cólon sigmoide
33.5 TPM
Esôfago - Junção
31.9 TPM
Útero
29.7 TPM
Cerebelo
29.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive distal spinal muscular atrophy 1Charcot-Marie-Tooth disease axonal type 2S
HGNC:5542UniProt:P38935
WARS1Tryptophan--tRNA ligase, cytoplasmicDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the attachment of tryptophan to tRNA(Trp) in a two-step reaction: tryptophan is first activated by ATP to form Trp-AMP and then transferred to the acceptor end of the tRNA(Trp) Has no angiostatic activity Possesses an angiostatic activity but has no aminoacylation activity (PubMed:11773625, PubMed:11773626, PubMed:14630953). Inhibits fluid shear stress-activated responses of endothelial cells (PubMed:14630953). Regulates ERK, Akt, and eNOS activation pathways that are associated with a

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 9

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND9 is characterized by juvenile onset of slowly progressive distal muscle weakness and atrophy affecting both the lower and upper limbs.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 9neurodevelopmental disorder with microcephaly and speech delay, with or without brain abnormalitiesautosomal recessive primary microcephalycomplex neurodevelopmental disorder
HGNC:12729UniProt:P23381
FILIP1Filamin-A-interacting protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

By acting through a filamin-A/F-actin axis, it controls the start of neocortical cell migration from the ventricular zone. May be able to induce the degradation of filamin-A

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
RHOD GTPase cycle
MECANISMO DE DOENÇA

Neuromuscular disorder, congenital, with dysmorphic facies

An autosomal recessive neuromuscular disorder characterized by multiple congenital joint contractures, hypotonia, muscle weakness, and facial dysmorphism. Patients may also exhibit motor delay, speech delay, impaired intellectual development, and abnormal brain imaging.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
25.2 TPM
Cólon sigmoide
21.2 TPM
Bladder
20.5 TPM
Artéria tibial
20.2 TPM
Coração - Átrio
18.1 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
neuromuscular disorder, congenital, with dysmorphic facies
HGNC:HGNC:21015UniProt:Q7Z7B0
DESDesminDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Muscle-specific type III intermediate filament essential for proper muscular structure and function. Plays a crucial role in maintaining the structure of sarcomeres, inter-connecting the Z-disks and forming the myofibrils, linking them not only to the sarcolemmal cytoskeleton, but also to the nucleus and mitochondria, thus providing strength for the muscle fiber during activity (PubMed:25358400). In adult striated muscle they form a fibrous network connecting myofibrils to each other and to the

LOCALIZAÇÃO

Cytoplasm, myofibril, sarcomere, Z lineCytoplasmCell membrane, sarcolemmaNucleusCell tipNucleus envelope

VIAS BIOLÓGICAS (1)
Striated Muscle Contraction
MECANISMO DE DOENÇA

Myopathy, myofibrillar, 1

A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM1 is characterized by skeletal muscle weakness associated with cardiac conduction blocks, arrhythmias, restrictive heart failure, and accumulation of desmin-reactive deposits in cardiac and skeletal muscle cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Muscular
14058.1 TPM
Cólon sigmoide
13011.1 TPM
Músculo esquelético
12069.4 TPM
Esôfago - Junção
10253.3 TPM
Coração - Ventrículo esquerdo
8346.0 TPM
OUTRAS DOENÇAS (4)
myofibrillar myopathy 1neurogenic scapuloperoneal syndrome, Kaeser typedilated cardiomyopathy 1Ifamilial isolated dilated cardiomyopathy
HGNC:2770UniProt:P17661
SQSTM1Sequestosome-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Molecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed:15340068, PubMed:15953362, PubMed:16286508, PubMed:17580304, PubMed:20168092, PubMed:22017874, PubMed:22622177, PubMed:24128730, PubMed:28404643, PubMed:29343546, PubMed:29507397, PubMed:31857589, PubMed:33509017, PubMed:34471133, PubMed:34893540, PubMed:35831301, PubMed:37306101, PubMed:37802024). Promotes the recruitment of ubiquitinated cargo

LOCALIZAÇÃO

Cytoplasmic vesicle, autophagosomePreautophagosomal structureCytoplasm, cytosolNucleus, PML bodyLate endosomeLysosomeNucleusEndoplasmic reticulumCytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (9)
PINK1-PRKN Mediated MitophagyPexophagyNF-kB is activated and signals survivalp75NTR recruits signalling complexesInterleukin-1 signaling
MECANISMO DE DOENÇA

Paget disease of bone 3

A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
155.2 TPM
Artéria tibial
140.4 TPM
Aorta
135.6 TPM
Fibroblastos
134.0 TPM
Glândula adrenal
131.3 TPM
OUTRAS DOENÇAS (8)
Paget disease of bone 3myopathy, distal, with rimmed vacuolesneurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 3
HGNC:11280UniProt:Q13501
MUSKMuscle, skeletal receptor tyrosine-protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Receptor tyrosine kinase which plays a central role in the formation and the maintenance of the neuromuscular junction (NMJ), the synapse between the motor neuron and the skeletal muscle (PubMed:25537362). Recruitment of AGRIN by LRP4 to the MUSK signaling complex induces phosphorylation and activation of MUSK, the kinase of the complex. The activation of MUSK in myotubes regulates the formation of NMJs through the regulation of different processes including the specific expression of genes in s

LOCALIZAÇÃO

Postsynaptic cell membrane

VIAS BIOLÓGICAS (1)
ECM proteoglycans
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS9 is a disorder of postsynaptic neuromuscular transmission, due to deficiency of AChR at the endplate that results in low amplitude of the miniature endplate potential and current.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Baixa expressão)
Intestino delgado
3.1 TPM
Bladder
1.9 TPM
Testículo
1.8 TPM
Músculo esquelético
1.7 TPM
Pulmão
1.5 TPM
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 9fetal akinesia deformation sequence 1postsynaptic congenital myasthenic syndrome
HGNC:7525UniProt:O15146
AGRNAgrinDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Depending on alternative splicing and post-translational modifications, it has a role in different processes, including neuromuscular junction formation and maintenance, and regulation of neurite outgrowth (By similarity). Also involved in positive regulation of cartilage formation through alpha-dystroglycan binding and up-regulation of SOX9 (PubMed:26290588) Heparan sulfate basal lamina glycoprotein that plays a central role in the formation and the maintenance of the neuromuscular junction (NM

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixSynapseCell membrane

VIAS BIOLÓGICAS (1)
Glycosaminoglycan-protein linkage region biosynthesis
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 8

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS8 is an autosomal recessive disease characterized by prominent defects of both the pre- and postsynaptic regions. Affected individuals have onset of muscle weakness in early childhood; the severity of the weakness and muscles affected is variable.

OUTRAS DOENÇAS (2)
congenital myasthenic syndrome 8postsynaptic congenital myasthenic syndrome
HGNC:329UniProt:O00468
CHRNB1Acetylcholine receptor subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 2A, slow-channel

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS2A is a slow-channel myasthenic syndrome. It is caused by kinetic abnormalities of the AChR, resulting in prolonged AChR channel opening episodes, prolonged endplate currents, and depolarization block. This is associated with calcium overload, which may contribute to subsequent degeneration of the endplate and postsynaptic membrane.

OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 2Acongenital myasthenic syndrome 2Cpostsynaptic congenital myasthenic syndrome
HGNC:1961UniProt:P11230
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
POMT2Protein O-mannosyl-transferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
B3GALNT2UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3

LOCALIZAÇÃO

Golgi apparatus membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11muscular dystrophy-dystroglycanopathy, type Aautosomal recessive non-syndromic intellectual disabilitymuscle-eye-brain disease
HGNC:28596UniProt:Q8NCR0
TCAPTelethoninDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Muscle assembly regulating factor. Mediates the antiparallel assembly of titin (TTN) molecules at the sarcomeric Z-disk

LOCALIZAÇÃO

Cytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (1)
Striated Muscle Contraction
MECANISMO DE DOENÇA

Cardiomyopathy, familial hypertrophic, 25

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2504.5 TPM
Coração - Ventrículo esquerdo
1812.2 TPM
Coração - Átrio
1252.5 TPM
Cerebelo
14.4 TPM
Cérebro - Hemisfério cerebelar
12.1 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Ghypertrophic cardiomyopathy 25familial isolated dilated cardiomyopathy
HGNC:11610UniProt:O15273
DYSFDysferlinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress (By similarity)

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasmic vesicle membraneCell membraneLate endosome membrane

VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 2

An autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
164.1 TPM
Baço
67.3 TPM
Músculo esquelético
44.4 TPM
Pulmão
30.5 TPM
Cólon sigmoide
23.4 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Bdistal myopathy with anterior tibial onsetMiyoshi muscular dystrophy 1autosomal recessive limb-girdle muscular dystrophy
HGNC:3097UniProt:O75923
POLGDNA polymerase subunit gamma-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of DNA polymerase gamma solely responsible for replication of mitochondrial DNA (mtDNA). Replicates both heavy and light strands of the circular mtDNA genome using a single-stranded DNA template, RNA primers and the four deoxyribonucleoside triphosphates as substrates (PubMed:11477093, PubMed:11897778, PubMed:15917273, PubMed:19837034, PubMed:9558343). Has 5' -> 3' polymerase activity. Functionally interacts with TWNK and SSBP1 at the replication fork to form a highly processiv

LOCALIZAÇÃO

MitochondrionMitochondrion matrix, mitochondrion nucleoid

VIAS BIOLÓGICAS (1)
Strand-asynchronous mitochondrial DNA replication
MECANISMO DE DOENÇA

Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 1

A disorder characterized by progressive weakness of ocular muscles and levator muscle of the upper eyelid. In a minority of cases, it is associated with skeletal myopathy, which predominantly involves axial or proximal muscles and which causes abnormal fatigability and even permanent muscle weakness. Ragged-red fibers and atrophy are found on muscle biopsy. A large proportion of chronic ophthalmoplegias are associated with other symptoms, leading to a multisystemic pattern of this disease. Additional symptoms are variable, and may include cataracts, hearing loss, sensory axonal neuropathy, ataxia, depression, hypogonadism, and parkinsonism.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
48.3 TPM
Linfócitos
42.0 TPM
Baço
41.5 TPM
Útero
40.9 TPM
Pulmão
38.7 TPM
OUTRAS DOENÇAS (11)
sensory ataxic neuropathy, dysarthria, and ophthalmoparesismitochondrial DNA depletion syndrome 4bmitochondrial DNA depletion syndrome 4amitochondrial disease
HGNC:9179UniProt:P54098
PRDX1Peroxiredoxin-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Thiol-specific peroxidase that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohols, respectively. Plays a role in cell protection against oxidative stress by detoxifying peroxides and as sensor of hydrogen peroxide-mediated signaling events. Might participate in the signaling cascades of growth factors and tumor necrosis factor-alpha by regulating the intracellular concentrations of H(2)O(2) (PubMed:9497357). Reduces an intramolecular disulfide bond in G

LOCALIZAÇÃO

CytoplasmMelanosome

VIAS BIOLÓGICAS (4)
TP53 Regulates Metabolic GenesNFE2L2 regulating anti-oxidant/detoxification enzymesDetoxification of Reactive Oxygen SpeciesDeregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
790.6 TPM
Tireoide
635.9 TPM
Linfócitos
598.5 TPM
Fibroblastos
487.5 TPM
Brain Spinal cord cervical c-1
472.8 TPM
OUTRAS DOENÇAS (1)
methylmalonic aciduria and homocystinuria type cblC
HGNC:HGNC:9352UniProt:Q06830
HEXABeta-hexosaminidase subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Hydrolyzes the non-reducing end N-acetyl-D-hexosamine and/or sulfated N-acetyl-D-hexosamine of glycoconjugates, such as the oligosaccharide moieties from proteins and neutral glycolipids, or from certain mucopolysaccharides (PubMed:11707436, PubMed:8123671, PubMed:8672428, PubMed:9694901). The isozyme S is as active as the isozyme A on the anionic bis-sulfated glycans, the chondroitin-6-sulfate trisaccharide (C6S-3), and the dermatan sulfate pentasaccharide, and the sulfated glycosphingolipid SM

LOCALIZAÇÃO

Lysosome

VIAS BIOLÓGICAS (1)
Defective HEXA causes GM2G1 (Hyaluronan metabolism)
MECANISMO DE DOENÇA

GM2-gangliosidosis 1

An autosomal recessive lysosomal storage disease marked by the accumulation of GM2 gangliosides in the neuronal cells. It is characterized by GM2 gangliosides accumulation in the absence of HEXA activity, leading to neurodegeneration and, in the infantile form, death in early childhood. It exists in several forms: infantile (most common and most severe), juvenile and adult (late-onset).

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
43.9 TPM
Fibroblastos
39.7 TPM
Cervix Endocervix
36.7 TPM
Aorta
36.0 TPM
Pulmão
34.0 TPM
OUTRAS DOENÇAS (4)
Tay-Sachs diseaseTay-Sachs disease, b variant, infantile formTay-Sachs disease, B variant, adult formTay-Sachs disease, b variant, juvenile form
HGNC:4878UniProt:P06865
CHCHD10Coiled-coil-helix-coiled-coil-helix domain-containing protein 10, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure

LOCALIZAÇÃO

Mitochondrion intermembrane space

VIAS BIOLÓGICAS (1)
Mitochondrial protein import
MECANISMO DE DOENÇA

Frontotemporal dementia and/or amyotrophic lateral sclerosis 2

A neurodegenerative disorder characterized by frontotemporal dementia and/or amyotrophic lateral sclerosis in affected individuals. There is high intrafamilial variation. Frontotemporal dementia is characterized by frontal and temporal lobe atrophy associated with neuronal loss, gliosis, and dementia. Patients exhibit progressive changes in social, behavioral, and/or language function. Amyotrophic lateral sclerosis is characterized by the death of motor neurons in the brain, brainstem, and spinal cord, resulting in fatal paralysis.

OUTRAS DOENÇAS (5)
lower motor neuron syndrome with late-adult onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 2autosomal dominant mitochondrial myopathy with exercise intoleranceamyotrophic lateral sclerosis
HGNC:15559UniProt:Q8WYQ3
SELENOIEthanolaminephosphotransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Ethanolaminephosphotransferase that catalyzes the transfer of phosphoethanolamine (PE) from CDP-ethanolamine to lipid acceptors, the final step in the synthesis of PE via the 'Kennedy' pathway (PubMed:17132865, PubMed:28052917, PubMed:29500230). PE is the second most abundant phospholipid of membranes in mammals and is involved in various membrane-related cellular processes (PubMed:17132865). The enzyme is critical for the synthesis of several PE species and also catalyzes the synthesis of plasm

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of PE
MECANISMO DE DOENÇA

Spastic paraplegia 81, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG81 is a complicated form characterized by white matter abnormalities, hypomyelination with progressive white matter loss, delayed motor development, progressive spasticity, and impaired intellectual development and speech delay. Additional features may include bifid uvula, microcephaly, seizures, and variable ocular anomalies.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
28.6 TPM
Skin Not Sun Exposed Suprapubic
23.1 TPM
Skin Sun Exposed Lower leg
22.1 TPM
Cerebelo
19.0 TPM
Linfócitos
17.6 TPM
OUTRAS DOENÇAS (2)
spastic paraplegia 81, autosomal recessiveautosomal recessive complex spastic paraplegia due to kennedy pathway dysfunction
HGNC:29361UniProt:Q9C0D9
NIPA1Magnesium transporter NIPA1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a Mg(2+) transporter. Can also transport other divalent cations such as Fe(2+), Sr(2+), Ba(2+), Zn(2+) and Co(2+) but to a much less extent than Mg(2+) (By similarity)

LOCALIZAÇÃO

Cell membraneEarly endosome

VIAS BIOLÓGICAS (1)
Miscellaneous transport and binding events
MECANISMO DE DOENÇA

Spastic paraplegia 6, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
66.2 TPM
Substância negra
32.7 TPM
Linfócitos
25.2 TPM
Hipotálamo
22.9 TPM
Brain Frontal Cortex BA9
22.2 TPM
OUTRAS DOENÇAS (2)
hereditary spastic paraplegia 6chromosome 15q11.2 deletion syndrome
HGNC:17043UniProt:Q7RTP0
KIF1AKinesin-like protein KIF1ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Kinesin motor with a plus-end-directed microtubule motor activity (By similarity). It is required for anterograde axonal transport of synaptic vesicle precursors (PubMed:33880452). Also required for neuronal dense core vesicles (DCVs) transport to the dendritic spines and axons. The interaction calcium-dependent with CALM1 increases vesicle motility and interaction with the scaffolding proteins PPFIA2 and TANC2 recruits DCVs to synaptic sites

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, neuron projectionCell projection, axonCytoplasm, perinuclear regionSynapseCytoplasmic vesicle, secretory vesicle, neuronal dense core vesicle membrane

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spastic paraplegia 30A, autosomal dominant

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG30A patients have a pure form of the disorder, limited to spastic paraplegia, whereas others may have a complicated form that includes additional features such as cognitive dysfunction, learning disabilities, peripheral sensorimotor neuropathy, urinary sphincter problems, and/or cerebellar atrophy. SPG30A is characterized by onset in the first or second decades of unsteady spastic gait and hyperreflexia of the lower limbs. Inheritance is autosomal dominant.

EXPRESSÃO TECIDUAL(Tecido-específico)
Córtex cerebral
331.8 TPM
Brain Frontal Cortex BA9
301.8 TPM
Cerebelo
266.3 TPM
Brain Anterior cingulate cortex BA24
262.4 TPM
Cérebro - Hemisfério cerebelar
235.1 TPM
OUTRAS DOENÇAS (5)
spastic paraplegia 30b, autosomal recessiveneuropathy, hereditary sensory, type 2Cintellectual disability, autosomal dominant 9hereditary sensory and autonomic neuropathy type 2
HGNC:888UniProt:Q12756
KIF1CKinesin-like protein KIF1CDisease-causing germline mutation(s) inRestrito
FUNÇÃO

Motor required for the retrograde transport of Golgi vesicles to the endoplasmic reticulum. Has a microtubule plus end-directed motility

LOCALIZAÇÃO

Cytoplasm, cytoskeleton

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Spastic ataxia 2, autosomal recessive

A neurologic disorder characterized by cerebellar ataxia, dysarthria, and variable spasticity of the lower limbs. Cognition is not affected.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
308.2 TPM
Brain Spinal cord cervical c-1
252.4 TPM
Substância negra
164.6 TPM
Artéria tibial
160.2 TPM
Aorta
151.4 TPM
OUTRAS DOENÇAS (1)
spastic ataxia 2
HGNC:6317UniProt:O43896
PEX16Peroxisomal membrane protein PEX16Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Required for peroxisome membrane biogenesis. May play a role in early stages of peroxisome assembly. Can recruit other peroxisomal proteins, such as PEX3 and PMP34, to de novo peroxisomes derived from the endoplasmic reticulum (ER). May function as receptor for PEX3

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (1)
Class I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 9

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
31.4 TPM
Testículo
30.9 TPM
Tireoide
24.5 TPM
Nervo tibial
23.1 TPM
Brain Spinal cord cervical c-1
22.4 TPM
OUTRAS DOENÇAS (5)
peroxisome biogenesis disorder 8A (Zellweger)peroxisome biogenesis disorder 8BZellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8857UniProt:Q9Y5Y5
PEX6Peroxisomal ATPase PEX6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA ATPase complex is

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membraneCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 4

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Fallopian Tube
66.8 TPM
Ovário
64.6 TPM
Cerebelo
61.1 TPM
Cérebro - Hemisfério cerebelar
58.5 TPM
Pituitária
55.1 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 4Bperoxisome biogenesis disorder 4A (Zellweger)peroxisome biogenesis disorder due to PEX6 defectobsolete Heimler syndrome
HGNC:8859UniProt:Q13608
PEX12Peroxisome assembly protein 12Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of a retrotranslocation channel required for peroxisome organization by mediating export of the PEX5 receptor from peroxisomes to the cytosol, thereby promoting PEX5 recycling (PubMed:24662292, PubMed:9354782, PubMed:9632816). The retrotranslocation channel is composed of PEX2, PEX10 and PEX12; each subunit contributing transmembrane segments that coassemble into an open channel that specifically allows the passage of PEX5 through the peroxisomal membrane (By similarity). PEX12 also re

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (3)
Peroxisomal protein importE3 ubiquitin ligases ubiquitinate target proteinsClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 3

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
12.5 TPM
Fibroblastos
11.2 TPM
Pituitária
10.1 TPM
Glândula adrenal
9.2 TPM
Nervo tibial
9.2 TPM
OUTRAS DOENÇAS (4)
peroxisome biogenesis disorder type 3Bperoxisome biogenesis disorder 3A (Zellweger)Zellweger spectrum disordersobsolete neonatal adrenoleukodystrophy
HGNC:8854UniProt:O00623
PEX1Peroxisomal ATPase PEX1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the PEX1-PEX6 AAA ATPase complex, a protein dislocase complex that mediates the ATP-dependent extraction of the PEX5 receptor from peroxisomal membranes, an essential step for PEX5 recycling (PubMed:11439091, PubMed:16314507, PubMed:16854980, PubMed:21362118, PubMed:29884772). Specifically recognizes PEX5 monoubiquitinated at 'Cys-11', and pulls it out of the peroxisome lumen through the PEX2-PEX10-PEX12 retrotranslocation channel (PubMed:29884772). Extraction by the PEX1-PEX6 AAA A

LOCALIZAÇÃO

Cytoplasm, cytosolPeroxisome membrane

VIAS BIOLÓGICAS (1)
Peroxisomal protein import
MECANISMO DE DOENÇA

Peroxisome biogenesis disorder complementation group 1

A peroxisomal disorder arising from a failure of protein import into the peroxisomal membrane or matrix. The peroxisome biogenesis disorders (PBD group) are genetically heterogeneous with at least 14 distinct genetic groups as concluded from complementation studies. Include disorders are: Zellweger syndrome (ZWS), neonatal adrenoleukodystrophy (NALD), infantile Refsum disease (IRD), and classical rhizomelic chondrodysplasia punctata (RCDP). ZWS, NALD and IRD are distinct from RCDP and constitute a clinical continuum of overlapping phenotypes known as the Zellweger spectrum (PBD-ZSS).

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
23.8 TPM
Nervo tibial
23.3 TPM
Cervix Endocervix
23.1 TPM
Tireoide
21.9 TPM
Cerebelo
21.8 TPM
OUTRAS DOENÇAS (6)
peroxisome biogenesis disorder 1Bperoxisome biogenesis disorder 1A (Zellweger)peroxisome biogenesis disorder due to PEX1 defectZellweger spectrum disorders
HGNC:8850UniProt:O43933
SLC5A6Sodium-dependent multivitamin transporterDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Sodium-dependent multivitamin transporter that mediates the electrogenic transport of pantothenate, biotin, lipoate and iodide (PubMed:10329687, PubMed:15561972, PubMed:19211916, PubMed:20980265, PubMed:21570947, PubMed:22015582, PubMed:25809983, PubMed:25971966, PubMed:27904971, PubMed:28052864, PubMed:31754459). Functions as a Na(+)-coupled substrate symporter where the stoichiometry of Na(+):substrate is 2:1, creating an electrochemical Na(+) gradient used as driving force for substrate uptak

LOCALIZAÇÃO

Cell membraneApical cell membrane

VIAS BIOLÓGICAS (3)
Transport of vitamins, nucleosides, and related moleculesBiotin transport and metabolismVitamin B5 (pantothenate) metabolism
MECANISMO DE DOENÇA

Sodium-dependent multivitamin transporter deficiency

An autosomal recessive multisystemic metabolic disorder characterized by early infantile onset, progressive neurodegeneration, global developmental delay, and developmental regression with loss of early motor and cognitive milestones. Additional variable features include seizures, ataxia, spasticity, peripheral neuropathy, immune defects, and osteopenia. Treatment with biotin, pantothenic acid, and lipoate may result in clinical improvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
80.0 TPM
Fígado
67.6 TPM
Mama
48.9 TPM
Útero
40.2 TPM
Linfócitos
38.0 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
peripheral motor neuropathy, childhood-onset, biotin-responsiveneurodegeneration, infantile-onset, biotin-responsive
HGNC:HGNC:11041UniProt:Q9Y289
SMPD1Sphingomyelin phosphodiesteraseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts sphingomyelin to ceramide (PubMed:12563314, PubMed:1840600, PubMed:18815062, PubMed:25339683, PubMed:25920558, PubMed:27659707, PubMed:33163980). Exists as two enzymatic forms that arise from alternative trafficking of a single protein precursor, one that is targeted to the endolysosomal compartment, whereas the other is released extracellularly (PubMed:20807762, PubMed:21098024, PubMed:9660788). However, in response to various forms of stress, lysosomal exocytosis may represent a major

LOCALIZAÇÃO

LysosomeLipid dropletSecretedSecreted, extracellular space

VIAS BIOLÓGICAS (1)
Glycosphingolipid catabolism
MECANISMO DE DOENÇA

Niemann-Pick disease A

An early-onset lysosomal storage disorder caused by failure to hydrolyze sphingomyelin to ceramide. It results in the accumulation of sphingomyelin and other metabolically related lipids in reticuloendothelial and other cell types throughout the body, leading to cell death. Niemann-Pick disease type A is a primarily neurodegenerative disorder characterized by onset within the first year of life, intellectual disability, digestive disorders, failure to thrive, major hepatosplenomegaly, and severe neurologic symptoms. The severe neurological disorders and pulmonary infections lead to an early death, often around the age of four. Clinical features are variable. A phenotypic continuum exists between type A (basic neurovisceral) and type B (purely visceral) forms of Niemann-Pick disease, and the intermediate types encompass a cluster of variants combining clinical features of both types A and B.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
79.4 TPM
Tireoide
67.2 TPM
Pituitária
65.9 TPM
Aorta
63.0 TPM
Cerebelo
61.4 TPM
OUTRAS DOENÇAS (2)
Niemann-Pick disease type BNiemann-Pick disease type A
HGNC:11120UniProt:P17405
PDXKPyridoxal kinaseDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalyzes the phosphorylation of the dietary vitamin B6 vitamers pyridoxal (PL), pyridoxine (PN) and pyridoxamine (PM) to form pyridoxal 5'-phosphate (PLP), pyridoxine 5'-phosphate (PNP) and pyridoxamine 5'-phosphate (PMP), respectively (Probable) (PubMed:10987144, PubMed:17766369, PubMed:19351586, PubMed:31187503, PubMed:9099727). PLP is the active form of vitamin B6, and acts as a cofactor for over 140 different enzymatic reactions

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Vitamin B6 activation to pyridoxal phosphate
MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6C, with optic atrophy

An autosomal recessive neurologic disorder characterized by childhood onset of axonal, sensorimotor polyneuropathy affecting mainly the lower limbs, and adult-onset optic atrophy. Clinical features include progressive distal muscle weakness and atrophy, significant standing and walking difficulties, areflexia, neurogenic pain and progressive visual impairment.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
123.5 TPM
Córtex cerebral
62.5 TPM
Brain Frontal Cortex BA9
58.9 TPM
Brain Anterior cingulate cortex BA24
53.9 TPM
Pituitária
50.0 TPM
OUTRAS DOENÇAS (1)
neuropathy, hereditary motor and sensory, type VIc, with optic atrophy
HGNC:HGNC:8819UniProt:O00764
VWA1von Willebrand factor A domain-containing protein 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Promotes matrix assembly (By similarity). Involved in the organization of skeletal muscles and in the formation of neuromuscular junctions (Probable)

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Neuronopathy, hereditary motor, autosomal recessive 7

An autosomal recessive, neuromyopathic disorder that manifests in childhood or adulthood with proximal and distal muscle weakness predominantly of the lower limbs. Affected individuals have difficulty climbing stairs and problems standing on the heels. Most patients have foot deformities, and some may have leg muscle atrophy. Muscle biopsy and electrophysiologic studies are consistent with both a myopathic process and an axonal motor neuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
196.9 TPM
Próstata
99.7 TPM
Bladder
93.6 TPM
Esôfago - Muscular
81.6 TPM
Cólon sigmoide
79.6 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neuronopathy, distal hereditary motor, autosomal recessive 7neuronopathy, distal hereditary motor, autosomal recessive 5
HGNC:30910UniProt:Q6PCB0
SLC5A7High affinity choline transporter 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

High-affinity Na(+)-coupled choline transmembrane symporter (PubMed:11027560, PubMed:11068039, PubMed:12237312, PubMed:12969261, PubMed:17005849, PubMed:23132865, PubMed:23141292, PubMed:27569547). Functions as an electrogenic, voltage-dependent transporter with variable charge/choline stoichiometry (PubMed:17005849). Choline uptake and choline-induced current is also Cl(-)-dependent where Cl(-) is likely a regulatory ion rather than cotransported ion (PubMed:11068039, PubMed:12237312, PubMed:17

LOCALIZAÇÃO

Presynaptic cell membraneCell projection, axonEarly endosome membraneCytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane

VIAS BIOLÓGICAS (2)
SLC-mediated bile acid transportAcetylcholine Neurotransmitter Release Cycle
MECANISMO DE DOENÇA

Neuronopathy, distal hereditary motor, autosomal dominant 7

A form of distal hereditary motor neuronopathy, a heterogeneous group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. HMND7 is characterized by onset in the second decade of progressive distal muscle wasting and weakness affecting the upper and lower limbs and resulting in walking difficulties and hand grip. There is significant muscle atrophy of the hands and lower limbs. The disorder is associated with vocal cord paresis due to involvement of the tenth cranial nerve.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
3.2 TPM
Esôfago - Junção
1.8 TPM
Brain Putamen basal ganglia
1.6 TPM
Bladder
1.6 TPM
Esôfago - Muscular
1.5 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (3)
neuronopathy, distal hereditary motor, type 7Acongenital myasthenic syndrome 20distal hereditary motor neuropathy type 7
HGNC:14025UniProt:Q9GZV3
GARS1Glycine--tRNA ligaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the ATP-dependent ligation of glycine to the 3'-end of its cognate tRNA, via the formation of an aminoacyl-adenylate intermediate (Gly-AMP) (PubMed:17544401, PubMed:24898252, PubMed:28675565). Also produces diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Thereby, may play a special role in Ap4A homeostasis (PubMed:19710017)

LOCALIZAÇÃO

CytoplasmCell projection, axonSecretedSecreted, extracellular exosomeMitochondrion

VIAS BIOLÓGICAS (1)
Cytosolic tRNA aminoacylation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, axonal, type 2D

A dominant axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal degeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy.

OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, type 5ACharcot-Marie-Tooth disease type 2Dspinal muscular atrophy, infantile, James typeneuronopathy, distal hereditary motor, type 5
HGNC:4162UniProt:P41250
SYT2Synaptotagmin-2Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Exhibits calcium-dependent phospholipid and inositol polyphosphate binding properties (By similarity). May have a regulatory role in the membrane interactions during trafficking of synaptic vesicles at the active zone of the synapse (By similarity). Plays a role in dendrite formation by melanocytes (PubMed:23999003)

LOCALIZAÇÃO

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneCytoplasmic vesicle, secretory vesicle, chromaffin granule membraneCytoplasm

VIAS BIOLÓGICAS (3)
Toxicity of botulinum toxin type B (botB)Clathrin-mediated endocytosisCargo recognition for clathrin-mediated endocytosis
MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 7A, presynaptic, and distal motor neuropathy, autosomal dominant

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness. CMS7A is an autosomal dominant, presynaptic disorder resembling Lambert-Eaton myasthenic syndrome. Affected individuals have a variable degree of proximal and distal limb weakness, muscle fatigue that improves with rest, mild gait difficulties, and reduced or absent deep tendon reflexes.

EXPRESSÃO TECIDUAL(Tecido-específico)
Cérebro - Hemisfério cerebelar
71.2 TPM
Cerebelo
57.2 TPM
Brain Frontal Cortex BA9
5.0 TPM
Brain Caudate basal ganglia
3.4 TPM
Brain Nucleus accumbens basal ganglia
2.6 TPM
OUTRAS DOENÇAS (2)
myasthenic syndrome, congenital, 7B, presynaptic, autosomal recessivecongenital myasthenic syndrome 7
HGNC:11510UniProt:Q8N9I0
SLC25A1Tricarboxylate transport protein, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Mitochondrial electroneutral antiporter that exports citrate from the mitochondria into the cytosol in exchange for malate (PubMed:26870663, PubMed:29031613, PubMed:29238895, PubMed:39881208, PubMed:38937634). Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis-aconitate and to a lesser extent trans-aconitate, maleate and succinate (PubMed:29031613). Substrate exchange across the membrane occurs consecutively with one substrate being transported first, then diss

LOCALIZAÇÃO

Mitochondrion inner membrane

VIAS BIOLÓGICAS (1)
Organic anion transport by SLC5/17/25 transporters
MECANISMO DE DOENÇA

Combined D-2- and L-2-hydroxyglutaric aciduria

An autosomal recessive neurometabolic disorder characterized by neonatal-onset encephalopathy with severe muscular weakness, intractable seizures, respiratory distress, and lack of psychomotor development resulting in early death. Brain imaging shows abnormalities including enlarged ventricles, delayed myelination, and germinal layer cysts.

EXPRESSÃO TECIDUAL(Ubíquo)
Tecido adiposo
147.1 TPM
Adipose Visceral Omentum
139.8 TPM
Fígado
126.2 TPM
Fibroblastos
124.7 TPM
Artéria tibial
104.4 TPM
OUTRAS DOENÇAS (2)
myasthenic syndrome, congenital, 23, presynapticD,L-2-hydroxyglutaric aciduria
HGNC:10979UniProt:P53007
CHRNA1Acetylcholine receptor subunit alphaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane Non functional acetylcholine receptor alpha subunit which is not integrated into functional acetylcholine-gated cation-selective channels

LOCALIZAÇÃO

Postsynaptic cell membraneCell membrane

VIAS BIOLÓGICAS (2)
Highly calcium permeable nicotinic acetylcholine receptorsHighly calcium permeable postsynaptic nicotinic acetylcholine receptors
MECANISMO DE DOENÇA

Multiple pterygium syndrome, lethal type

Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent.

OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 1Alethal multiple pterygium syndromemyasthenic syndrome, congenital, 1B, fast-channelpostsynaptic congenital myasthenic syndrome
HGNC:1955UniProt:P02708
ALG2Programmed cell death protein 6Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium sensor that plays a key role in processes such as endoplasmic reticulum (ER)-Golgi vesicular transport, endosomal biogenesis or membrane repair. Acts as an adapter that bridges unrelated proteins or stabilizes weak protein-protein complexes in response to calcium: calcium-binding triggers exposure of apolar surface, promoting interaction with different sets of proteins thanks to 3 different hydrophobic pockets, leading to translocation to membranes (PubMed:20691033, PubMed:25667979). Inv

LOCALIZAÇÃO

Endoplasmic reticulum membraneCytoplasmic vesicle, COPII-coated vesicle membraneCytoplasmNucleusEndosome

VIAS BIOLÓGICAS (1)
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
OUTRAS DOENÇAS (3)
congenital myasthenic syndrome 14ALG2-congenital disorder of glycosylationobsolete congenital myasthenic syndromes with glycosylation defect
HGNC:23159UniProt:O75340
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
SGCDDelta-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 6

An autosomal recessive degenerative myopathy initially affecting the proximal limb girdle musculature. Muscle from patients shows a complete loss of delta-sarcoglycan as well as of the others components of the sarcoglycan complex.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
26.6 TPM
Aorta
20.2 TPM
Músculo esquelético
15.2 TPM
Esôfago - Junção
14.2 TPM
Coração - Átrio
12.8 TPM
OUTRAS DOENÇAS (4)
autosomal recessive limb-girdle muscular dystrophy type 2Fdilated cardiomyopathy 1Lautosomal recessive limb-girdle muscular dystrophyfamilial isolated dilated cardiomyopathy
HGNC:10807UniProt:Q92629
SPG21MaspardinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May play a role as a negative regulatory factor in CD4-dependent T-cell activation

LOCALIZAÇÃO

Cytoplasm, cytosolMembraneEndosome membraneGolgi apparatus, trans-Golgi network membrane

MECANISMO DE DOENÇA

Spastic paraplegia 21, autosomal recessive

A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG21 is associated with dementia and other central nervous system abnormalities. Subtle childhood abnormalities may be present, but the main features develop in early adulthood. The disease is slowly progressive, and cerebellar and extrapyramidal signs are also found in patients with advanced disease. Patients have a thin corpus callosum and white-matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
75.6 TPM
Cervix Endocervix
73.4 TPM
Cervix Ectocervix
65.7 TPM
Tireoide
62.3 TPM
Linfócitos
61.7 TPM
OUTRAS DOENÇAS (1)
mast syndrome
HGNC:20373UniProt:Q9NZD8
FHFumarate hydratase, mitochondrialDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the reversible stereospecific interconversion of fumarate to L-malate (PubMed:30761759). Experiments in other species have demonstrated that specific isoforms of this protein act in defined pathways and favor one direction over the other (Probable) Catalyzes the hydration of fumarate to L-malate in the tricarboxylic acid (TCA) cycle to facilitate a transition step in the production of energy in the form of NADH Catalyzes the dehydration of L-malate to fumarate (By similarity). Fumarate

LOCALIZAÇÃO

MitochondrionCytoplasm, cytosolNucleusChromosome

VIAS BIOLÓGICAS (2)
Citric acid cycle (TCA cycle)Mitochondrial protein degradation
MECANISMO DE DOENÇA

Fumarase deficiency

A severe autosomal recessive metabolic disorder characterized by early-onset hypotonia, profound psychomotor retardation, and brain abnormalities, such as agenesis of the corpus callosum, gyral defects, and ventriculomegaly. Many patients show neonatal distress, metabolic acidosis, and/or encephalopathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
139.4 TPM
Fibroblastos
128.8 TPM
Coração - Ventrículo esquerdo
120.5 TPM
Músculo esquelético
115.0 TPM
Fígado
104.5 TPM
OUTRAS DOENÇAS (3)
fumaric aciduriahereditary leiomyomatosis and renal cell cancerhereditary pheochromocytoma-paraganglioma
HGNC:3700UniProt:P07954

Variantes genéticas (ClinVar)

319 variantes patogênicas registradas no ClinVar.

🧬 TUBB3: NM_006086.4(TUBB3):c.847G>T (p.Ala283Ser) ()
🧬 TUBB3: NM_006086.4(TUBB3):c.880T>G (p.Phe294Val) ()
🧬 TUBB3: NM_006086.4(TUBB3):c.21C>G (p.Ile7Met) ()
🧬 TUBB3: NM_006086.4(TUBB3):c.98G>A (p.Ser33Asn) ()
🧬 TUBB3: NM_006086.4(TUBB3):c.941C>T (p.Ala314Val) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 3.786 variantes classificadas pelo ClinVar.

379
1136
2271
Patogênica (10.0%)
VUS (30.0%)
Benigna (60.0%)
VARIANTES MAIS SIGNIFICATIVAS
DYSF: NM_001130987.2(DYSF):c.1023C>A (p.Tyr341Ter) [Pathogenic]
DYSF: NM_001130987.2(DYSF):c.240-2A>G [Likely pathogenic]
DYSF: NM_001130987.2(DYSF):c.1003-18T>G [Uncertain significance]
DYSF: NM_001130987.2(DYSF):c.2626T>A (p.Phe876Ile) [Uncertain significance]
DYSF: NM_001130987.2(DYSF):c.2778G>A (p.Thr926=) [Uncertain significance]

Vias biológicas (Reactome)

200 vias biológicas associadas aos genes desta condição.

Translocation of SLC2A4 (GLUT4) to the plasma membrane Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane Gap junction assembly MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Recruitment of NuMA to mitotic centrosomes Prefoldin mediated transfer of substrate to CCT/TriC Formation of tubulin folding intermediates by CCT/TriC Post-chaperonin tubulin folding pathway Recycling pathway of L1 Hedgehog 'off' state Cargo trafficking to the periciliary membrane Intraflagellar transport RHO GTPases activate IQGAPs RHO GTPases Activate Formins COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint Carboxyterminal post-translational modifications of tubulin HCMV Early Events Assembly and cell surface presentation of NMDA receptors Activation of AMPK downstream of NMDARs Aggrephagy EML4 and NUDC in mitotic spindle formation Sealing of the nuclear envelope (NE) by ESCRT-III Kinesins tRNA processing in the nucleus Caspase-mediated cleavage of cytoskeletal proteins Neutrophil degranulation Sensory processing of sound by outer hair cells of the cochlea Amyloid fiber formation Cytosolic tRNA aminoacylation Sphingolipid de novo biosynthesis Matriglycan biosynthesis on DAG1 Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor RAF/MAP kinase cascade Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation ALKBH3 mediated reversal of alkylation damage Synthesis of dolichyl-phosphate mannose Synthesis of glycosylphosphatidylinositol (GPI) Defective DPM1 causes DPM1-CDG Defective DPM3 causes DPM3-CDG Defective DPM2 causes DPM2-CDG Maturation of DENV proteins snRNP Assembly SARS-CoV-2 modulates host translation machinery ABC-family proteins mediated transport Defective CFTR causes cystic fibrosis AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) Formation of the dystrophin-glycoprotein complex (DGC) CPT1B transfers PALM to CAR CPT1A transfers PALM to CAR VLDL assembly Chylomicron assembly LDL remodeling Defective MMADHC causes MMAHCD Defective MMACHC causes MAHCC Cobalamin (Cbl) metabolism Regulation of pyruvate dehydrogenase (PDH) complex Signaling by Retinoic Acid Mitochondrial protein degradation PDH complex synthesizes acetyl-CoA from PYR Lanosterol biosynthesis Protein lipoylation Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation ATF4 activates genes in response to endoplasmic reticulum stress mRNA decay by 3' to 5' exoribonuclease Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA KSRP (KHSRP) binds and destabilizes mRNA Major pathway of rRNA processing in the nucleolus and cytosol Nuclear RNA decay APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway Alanine metabolism Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation RAB GEFs exchange GTP for GDP on RABs Glutamate and glutamine metabolism Formation of ATP by chemiosmotic coupling Mitochondrial translation termination Cristae formation Regulation of CDH11 Expression and Function Regulation of CDH11 gene transcription Intracellular oxygen transport Mitochondrial unfolded protein response (UPRmt) NADE modulates death signalling Activation of BIM and translocation to mitochondria Activation of caspases through apoptosome-mediated cleavage Ubiquinol biosynthesis Export of Viral Ribonucleoproteins from Nucleus NEP/NS2 Interacts with the Cellular Export Machinery Respiratory electron transport Complex I biogenesis RAC1 GTPase cycle Degradation of the extracellular matrix Collagen degradation Collagen biosynthesis and modifying enzymes Signaling by PDGF Assembly of collagen fibrils and other multimeric structures Integrin cell surface interactions ECM proteoglycans NCAM1 interactions Collagen chain trimerization Ion homeostasis Ion transport by P-type ATPases Potential therapeutics for SARS Acyl chain remodeling of DAG and TAG Triglyceride biosynthesis MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis Defective LARGE causes MDDGA6 and MDDGB6 Budding and maturation of HIV virion Membrane binding and targetting of GAG proteins Endosomal Sorting Complex Required For Transport (ESCRT) HCMV Late Events Late endosomal microautophagy Expression and translocation of olfactory receptors E3 ubiquitin ligases ubiquitinate target proteins Peroxisomal protein import Pexophagy NOTCH2 Activation and Transmission of Signal to the Nucleus Expression of NOTCH2NL genes RHOD GTPase cycle Striated Muscle Contraction NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival PINK1-PRKN Mediated Mitophagy Neddylation Interleukin-1 signaling Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 Glycosaminoglycan-protein linkage region biosynthesis HS-GAG biosynthesis HS-GAG degradation Non-integrin membrane-ECM interactions Defective B4GALT7 causes EDS, progeroid type Defective B3GAT3 causes JDSSDHD Defective EXT2 causes exostoses 2 Defective EXT1 causes exostoses 1, TRPS2 and CHDS Defective B3GALT6 causes EDSP2 and SEMDJL1 Attachment and Entry Retinoid metabolism and transport Respiratory syncytial virus (RSV) attachment and entry RSV-host interactions Dengue Virus-Host Interactions Dengue Virus Attachment and Entry Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 DAG1 core M2 glycosylations DAG1 core M3 glycosylations DAG1 core M1 glycosylations Regulation of CDH1 posttranslational processing and trafficking to plasma membrane Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 Smooth Muscle Contraction Strand-asynchronous mitochondrial DNA replication Scavenging by Class B Receptors Detoxification of Reactive Oxygen Species TP53 Regulates Metabolic Genes Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models NFE2L2 regulating anti-oxidant/detoxification enzymes Keratan sulfate degradation CS/DS degradation Hyaluronan degradation Defective HEXA causes GM2G1 (Hyaluronan metabolism) Glycosphingolipid catabolism Mitochondrial protein import Synthesis of PE Miscellaneous transport and binding events Class I peroxisomal membrane protein import Biotin transport and metabolism Vitamin B5 (pantothenate) metabolism Transport of vitamins, nucleosides, and related molecules Vitamin B6 activation to pyridoxal phosphate Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) Post-translational protein phosphorylation Acetylcholine Neurotransmitter Release Cycle Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A) SLC-mediated bile acid transport Mitochondrial tRNA aminoacylation Toxicity of botulinum toxin type B (botB) Neurexins and neuroligins Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Organic anion transport by SLC5/17/25 transporters Highly calcium permeable postsynaptic nicotinic acetylcholine receptors Highly calcium permeable nicotinic acetylcholine receptors Defective ALG2 causes CDG-1i Defective ALG14 causes ALG14-CMS Regulation of expression of SLITs and ROBOs EGR2 and SOX10-mediated initiation of Schwann cell myelination Citric acid cycle (TCA cycle)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 21
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 2 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença neuromuscular

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

9.400 ensaios clínicos encontrados, 2 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
2.956 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 2.956

#1

Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.

Annals of clinical and translational neurology2026 Mar 19

Sarcoglycanopathies are among the most severe limb-girdle muscular dystrophies (LGMD), though milder presentations have been described. These diseases are primarily caused by missense variants, but the limited predictability of their effect on protein maturation, complex formation, and transport has hindered reliable genotype-phenotype correlations. This study aimed to establish accurate genotype-phenotype correlations for LGMDR3, LGMDR4, and LGMDR5. We analyzed the largest sarcoglycanopathy cohort to date (n = 541). Clinical data, including age at symptom onset and loss of ambulation, were collected and used to define phenotype severity. Predictive models were developed considering the impact of non-truncating variants on secondary structure, functional domains, evolutionary conservation, and intra-complex protein-protein interactions. Patients carrying two variants predicted to disrupt membrane trafficking were expected to present with severe phenotypes. For LGMDR3, the best-performing model classified variants affecting β-sheets, cadherin-like, and ATP-binding domains as disruptive to membrane translocation, achieving 89% predictive power, 0.867 balanced accuracy, and 2.4% false-negative rate (clinically severe patients who were wrongly classified by the model as mild). For LGMDR4 and LGMDR5, the best-performing model involved conserved residues, β-sheets, EGF-like domain, and protein-protein interactions-reaching 80% predictive power, 0.689 balanced accuracy, and 3.1% false-negative rate (LGMDR4), and 90% predictive power, 0.536 balanced accuracy, with no false negatives (LGMDR5). Additionally, we developed an open-access predictive tool for clinical and research application. This study provides a robust genotype-phenotype correlation for sarcoglycanopathies, improving prognosis, patient management, and clinical trial recruitment.

#2

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Molecular therapy : the journal of the American Society of Gene Therapy2026 Mar 11

Myotonic dystrophy type 1 (DM1) is a rare, autosomal dominant, progressive neuromuscular disease caused by the expansion of CTG repeats in the DM1 protein kinase (DMPK) gene. Expanded CUG repeats in the mutant DMPK transcript bind and sequester splicing factors, especially in the muscleblind-like (MBNL) family, leading to misregulated alternative splicing of mRNA, which is the main driver of DM1 pathology. We designed an antibody-oligonucleotide conjugate (AOC), delpacibart etedesiran (del-desiran), to deliver a DMPK-targeting small interfering RNA to muscle via transferrin receptor 1-mediated cell internalization. Del-desiran reduced mutDMPK mRNA expression, increased estimated levels of functional MBNL, and corrected disease-associated mis-splicing in a dose-dependent manner. The extent of increase in functional MBNL was associated with consistent trends toward muscle function improvement, confirming del-desiran's mechanism of action and supporting its development as a treatment for DM1. The translation of its pharmacodynamic activity from preclinical models (patient-derived myotubes and Macaca fascicularis [cynomolgus monkeys]) to patients with DM1 demonstrates del-desiran's consistency across species and reveals the potential broad utility of the AOC platform in further neuromuscular diseases.

#3

Expanding the phenotypic and immunological landscape of Alazami syndrome: Evidence from seven new patients with LARP7 gene variants.

European journal of pediatrics2026 Mar 11

Alazami syndrome is a neurodevelopmental disorder characterized by postnatal growth retardation, moderate to severe intellectual disability, and facial dysmorphology. It is caused by biallelic variants in the transcriptional regulator La ribonucleoprotein 7 (LARP7), where frameshift variants accounted for the majority of cases. The current study presents 7 new patients, including 3 males and 4 females from 3 unrelated families. Careful and thorough clinical examination identified novel oro-dental disease abnormalities, including a prominent premaxilla and enamel defects. The detected variants (c.1113_1116del, c.997 + 2T > C and c.518T > C) were not reported in the previous studies. The substitution c.518T > C represented the second missense variant to be identified in patients with Alazami syndrome. Male patients from the three families fulfilled ≥ 2 clinical warning signs of primary immunodeficiency. Lymphocyte subset counts and immunoglobulin levels were estimated in patients from two families. The values were within reference ranges, with only minor non-significant alterations in cytotoxic T-cell counts. A functional assay of B lymphocyte response was performed in one family, demonstrating impaired Streptococcus pneumoniae IgG antibody production following Pneumovax vaccination in the male patient, while his female sibling mounted an adequate response. In conclusion, the disease has a wide range of symptoms, which vary greatly among the affected patients. Our study expanded the clinical and molecular spectrum of the disorder and highlighted immunodeficiency as an underrecognized disease feature, potentially with a male sex predilection.

#4

Caring beyond the procedure: a qualitative study on thoracic surgery nurses' perspectives on chronic illness experiences of individuals with myasthenia gravis undergoing thymectomy.

BMJ open2026 Mar 09

To explore how thoracic surgical nurses perceive and respond to the chronic illness needs of individuals with myasthenia gravis undergoing thymectomy. Data were collected through four focus group interviews using a semi-structured interview guide. The analysis followed a hermeneutic approach, identifying recurring themes through iterative interpretation and critical reflection. Nineteen thoracic surgical nurses from ward and postanaesthesia care unit settings participated, representing a diverse range of clinical experience. The study followed the Consolidated Criteria for Reporting Qualitative Research (COREQ) checklist for reporting the findings of this study. The analysis identified three overarching themes reflecting nurses' experiences of caring for individuals with myasthenia gravis undergoing thymectomy. First, nurses described how the chronic aspects of the illness often 'disappeared' within the surgical care process, with attention focused mainly on procedural recovery, leaving patients' broader illness needs unaddressed. Second, nurses experienced a dilemma between providing acute surgical care and responding to patients' chronic illness understanding, highlighting uncertainty due to limited knowledge and lack of clear guidelines. Third, nurses emphasised the difficulty of managing the invisible and unpredictable symptoms of myasthenia gravis, which created a heightened need for vigilance but also uncertainty in symptom assessment and support. Across all themes, the findings suggest that surgical care practices may insufficiently recognise patients' ongoing illness experiences, emphasising the need for greater knowledge, interdisciplinary collaboration and chronic illness-sensitive care approaches. The study highlights the need for increased attention to chronic illness needs in surgical care, supporting interdisciplinary collaboration and tailored nursing practices that address the lived experiences of patients with chronic conditions.

#5

Climate change and brain health, a risk management approach focusing on the European region: A narrative review.

Journal of the neurological sciences2026 Apr 15

Among the myriad consequences of climate change, global warming and extreme weather events are particularly critical due to their well-documented impact on neurological and psychological well-being. However, the severity of these impacts varies significantly by geography. This article assesses the potential adverse effects of climate change on "brain health" through a risk management framework. The analysis begins by evaluating existing governance and risk-assessment procedures, followed by an examination of human adaptive capacities and natural risks. The latter draws upon climatological data-specifically regarding global warming and the "tropicalization" of the Euro-Mediterranean region-as well as anthropological insights. Building on this foundation, we propose strategies for effective risk control, including adaptation, mitigation, and preparedness. Success depends on the mobilization of public health researchers and professionals to drive organizational change and implement preventative measures to address extreme events. Consequently, the article advocates for specific decisions regarding communication, education, and early-warning systems to enhance rescue efficiency and prevent disasters. The discussion concludes with a focus on mitigation strategies specifically tailored to the Euro-Mediterranean region to address the challenges of climate tropicalization.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.087 artigos no totalmostrando 195

2026

Front-line systemic treatment outcomes in POEMS syndrome.

British journal of haematology
2026

A Qualitive Investigation of Geographic Disparities in Genetic Testing and Care Access for Amyotrophic Lateral Sclerosis: Insights From Patient Journey Mapping.

Patient preference and adherence
2026

Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study.

Molecular genetics and metabolism
2026

Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.

Neuromuscular disorders : NMD
2026

Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.

Annals of clinical and translational neurology
2026

Inflammatory signaling differentially changes chromatin accessibility and gene expression of the PD- associated kinase LRRK2 between human and mice.

Molecular neurodegeneration
2026

Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid-Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study.

Neuropathology and applied neurobiology
2026

Evaluating effects of risdiplam in adults with spinal muscular atrophy: a monocentric study.

ERJ open research
2026

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.

Muscle & nerve
2026

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Journal of neuromuscular diseases
2026

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

[Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
2026

Expanding the phenotypic and immunological landscape of Alazami syndrome: Evidence from seven new patients with LARP7 gene variants.

European journal of pediatrics
2025

The role of the pulmonary function laboratory in the assessment of adults with neuromuscular disease.

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
2026

Teaching NeuroImage: Superior Cerebellar Peduncle Tract Sign in SCA27B.

Neurology
2026

Caring beyond the procedure: a qualitative study on thoracic surgery nurses' perspectives on chronic illness experiences of individuals with myasthenia gravis undergoing thymectomy.

BMJ open
2026

Anaesthetic Management of a Patient With LDB3-Associated Myopathy Undergoing Prostate Biopsy Under Total Intravenous Anaesthesia: A Case Report.

Cureus
2026

How Is Lumbar Fusion Associated With Compensatory Hip Motion After THA?

Clinical orthopaedics and related research
2026

The evolving therapeutic landscape of spinal muscular atrophy - A scoping review of investigational agents, emerging delivery technologies and strategic innovations.

British journal of clinical pharmacology
2025

Rapsyn-acetylcholine receptor interactions: structural models inform mechanisms of clustering at the neuromuscular junction.

Biophysical reviews
2026

Climate change and brain health, a risk management approach focusing on the European region: A narrative review.

Journal of the neurological sciences
2026

MITOCHONDRIA IN MUSCLE STEM CELL BIOLOGY: GATEKEEPERS OF FATE, FUNCTION, AND REGENERATION.

American journal of physiology. Cell physiology
2026

Evaluation of Muscle Oxygenation by Functional Near-Infrared Spectroscopy in Patients with Myasthenia Gravis During Rest and Exercise.

Noro psikiyatri arsivi
2026

Ozone pollution as a possible trigger for multiple sclerosis in young people: the PEDIGREE study.

Journal of neurology
2026

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease
2026

Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model.

Cell death & disease
2026

The disclosure of a diagnosis of neuromuscular disease in adulthood: a qualitative study of patients' memories.

Journal of community genetics
2026

Intravenous methylprednisolone as add-on induction therapy for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.

Journal of neurology, neurosurgery, and psychiatry
2026

The Impact of Surgical Correction of Neuromuscular Scoliosis on Respiratory Muscle Function in Individuals with Spinal Muscular Atrophy-Preliminary Report.

Journal of clinical medicine
2026

Prospective Study of Video Hand Opening Time as a Quantitative Measurement of Myotonia in Patients With Myotonic Dystrophy Type 1.

Neurology
2026

The Calcium Connection: Explaining Motor Neuron Vulnerability in ALS.

Cells
2026

Pediatric toe-walking cohort with heterozygous SBF1 variants: A phenotypic description.

Global medical genetics
2026

Strategies to Increase Patients' Adherence to Digital Therapeutics for Musculoskeletal Diseases: A Narrative Review.

Yonsei medical journal
2026

Exercise mimetics as unexplored therapeutics for treating depression.

Molecular psychiatry
2026

Immediate and Sustained Effects of Intensive Equine-Assisted Physiotherapy Based on Neuroproprioceptive "Facilitation and Inhibition" on Psychomotor Development, Clinical Functions, Quality of Life, and Molecular Biological Indicators in Children With Spinal Muscular Atrophy: Protocol for a Crossover Randomized Controlled Trial.

JMIR research protocols
2026

An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.

The New England journal of medicine
2026

Reducing Early-Life Smoke Exposure as a Preventive Strategy for Pediatric Multiple Sclerosis: Results from the PEDIGREE Study.

Neurology and therapy
2026

Assessing the Relationship of Quality of Life With Functional Status in a Large Cohort of Adult Patients With Neuromuscular Disorders.

Neurology. Clinical practice
2026

Transition from ICU to home care with long-term invasive ventilation using a single-limb BiPAP circuit.

Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures)
2026

Swallowing development in infants and toddlers with spinal muscular atrophy following therapy compared to healthy controls: the prospective controlled DySMA trial.

Orphanet journal of rare diseases
2026

Effect of Preoperative Botulinum Toxin A on Pain and Opioid Consumption After Bilateral Sagittal Split Osteotomy.

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
2026

High-Altitude Travel in Patients With Neuromuscular Disease and Thoracic Restrictive Disorders: A Narrative Review.

Chest
2026

Takotsubo cardiomyopathy in myasthenia gravis: a systematic review of case reports with subtype-based analysis.

International journal of emergency medicine
2026

Participation experiences of young people with neuromuscular dystrophies and their parents: a qualitative dyadic analysis.

Disability and rehabilitation
2026

Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.

European journal of neurology
2026

Comparison of efficacy, tolerance, and professionals' opinions between plaster casting and 3D scanning in manufacturing the Garches brace.

Prosthetics and orthotics international
2026

Acute Liver Failure With Transient Liver Steatosis Following Multiple Hits Postoperatively in a Patient With Limb-Girdle Muscular Dystrophy: A Case Report.

Clinical case reports
2026

An updated review of the SMA clinical trial landscape in the United States: Findings from analysis of recruitment targets on ClinicalTrials.gov and a survey of SMA clinical trial sites on factors affecting site capacity and readiness.

Contemporary clinical trials communications
2026

Introduction to the Supplement.

Muscle & nerve
2025

From policy to practice: premarital spinal muscular atrophy screening as a public health initiative in northern Türkiye.

Frontiers in public health
2026

Benchmarking RNA-seq Tools for Real-World Diagnostic Applications.

medRxiv : the preprint server for health sciences
2026

Targeted knockdown of Smn in muscle stem cells induces non-cell autonomous loss of motor neurons.

Brain : a journal of neurology
2026

Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.

Therapeutic advances in rare disease
2026

Genetic variability in the PLIN4 gene: A new sequence duplication causing autophagic vacuolar myopathy.

Genes & diseases
2026

Disruptions of cell signaling pathways in myotonic dystrophy type 1 skeletal muscle, their pathogenic impact, and potential for combinatorial therapeutics.

The Journal of biological chemistry
2026

277th ENMC international workshop: Congenital myopathies: revising and revisiting nomenclature and diagnostic guidelines, 21-23 June 2024, Hoofddorp, The Netherlands.

Neuromuscular disorders : NMD
2026

Seronegative disseminated neosporosis with fatal outcome in an adult dog following prednisone therapy.

Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
2026

Neuromuscular ultrasound with superb microvascular imaging in muscular sarcoidosis: morphological features and treatment monitoring.

BMJ case reports
2025

ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals.

Frontiers in neurology
2026

The Spectrum of Motor Disorders in Patients with Chronic Kidney Disease: Pathogenic Mechanisms, Clinical Manifestations, and Therapeutic Strategies.

Journal of clinical medicine
2026

Myasthenia Gravis Outcomes After Use of Statins and Other Contraindicated Treatments: Results From the French National Insurance Database.

European journal of neurology
2025

Role of Polysomnography in Tracheostomy Decannulation in Neuromuscular Disease: A Case Report.

Cureus
2026

Directions for advancing prognostic assessments in multiple sclerosis: Qualitative Insights from MS specialist Interviews.

Journal of the neurological sciences
2026

Efficacy of radiotherapy and role of adjunctive immunochemotherapy in POEMS syndrome with solitary plasmacytoma.

Blood advances
2026

Tendon Transfer Fixation in Patients With Neuromuscular Disease.

Journal of the Pediatric Orthopaedic Society of North America
2026

Electrophysiological Changes in Pediatric Spinal Muscular Atrophy: Results From an Observational Study.

Muscle & nerve
2026

The alternative androgen receptor isoform A mitigates toxicity of polyglutamine-elongated mutant androgen receptor in spinal and bulbar muscular atrophy.

Journal of advanced research
2026

Linking allostatic load, heart rate variability and brain functional networks and structures in healthy men.

Psychoneuroendocrinology
2025

Evaluation of multiple generative large language models on neurology board-style questions.

Frontiers in digital health
2026

Sealing the Deal: Incisional Vacuum Assisted Closure Following Neuromuscular Posterior Spinal Fusion is Associated With a Lower Rate of Infection.

Journal of pediatric orthopedics
2026

Clinical features and treatment outcomes of POEMS-associated Castleman disease.

British journal of haematology
2026

Versatile role of fibro-adipogenic progenitors in neuromuscular junction homeostasis and pathology.

Biochemical and biophysical research communications
2026

Fiber-type-specific architecture and pathophysiology of the neuromuscular junction.

Neuroscience
2026

286th ENMC international workshop: Muscle imaging: artificial intelligence, automatic segmentation and imaging data sharing in neuromuscular disease. Hoofddorp, The Netherlands, 7-9 March 2025.

Neuromuscular disorders : NMD
2026

Perinatal management of a pregnant patient with limb-girdle muscular dystrophy R1 calpain3-related.

BMJ case reports
2026

Early Diagnosis of ATTR-CM Using Carpal Tunnel Biopsy Examination: EDUCATE: A United Kingdom Prospective Multicenter Study.

JACC. Heart failure
2026

Use of noninvasive positive pressure ventilation in patients admitted to the internal medicine service of a tertiary care hospital.

BMC research notes
2026

Environmental Determinants of Participation in Children With Duchenne Muscular Dystrophy.

Pediatric neurology
2026

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.

Muscle & nerve
2026

BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial.

Nature medicine
2026

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.

Nature medicine
2026

Dyspnea is related to clinical outcomes in patients weaning from invasive mechanical ventilation with tracheostomy: a multicenter prospective study.

Critical care (London, England)
2026

Neurological symptoms and physical exam findings 6-11 months post-COVID-19: a cohort study.

Scientific reports
2025

An original story of a coma.

Respiratory medicine and research
2025

Whole-Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies.

Annals of clinical and translational neurology
2025

The Emerging TNNT3 Spectrum: From Distal Arthrogryposis to Congenital Myopathy.

Human mutation
2025

Behavioral improvement in dystrophic mdx23 mouse following repeated antisense oligonucleotides injections.

Molecular therapy. Nucleic acids
2025

Artificial Intelligence-Driven Design of Antisense Oligonucleotides for Precision Medicine in Neuromuscular Disorders.

Genes
2025

Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System.

Cancers
2025

Bridging the Heterogeneity of Myasthenia Gravis Scores as a Foundational Step Towards the Construction of a Digital Twin.

Biomedicines
2026

Expression of genetic peripheral neuropathies in South African children.

Neuromuscular disorders : NMD
2025

Acute nutritional axonal neuropathy and Wernicke's encephalopathy status post Roux-en-Y gastric bypass.

BMJ case reports
2026

Mixed-effects additive Bayesian networks for the assessment of ruptured intracranial aneurysms: Insights from multicenter data.

Computers in biology and medicine
2026

Comprehensive Characterization of Spastic Paraplegia in Korean Patients: A Single-Center Experience over Two Decades.

Yonsei medical journal
2025

DYNC1H1 in Spinal Muscular Atrophy: Diagnostic Findings From Two Families and a Comprehensive Review of Its Role in Neuromuscular and Neurodevelopmental Disorders.

Molecular genetics & genomic medicine
2026

Sleep disorders in myasthenia gravis: A systematic review on prevalence, clinical associations, and the accuracy of assessment methodologies.

Sleep medicine
2025

2nd NMD4C basic research summer school on promoting standardized protocols to advance translational research in neuromuscular disorders.

Journal of neuromuscular diseases
2025

Operative management of enteral access in acute care surgery-What you need to know.

The journal of trauma and acute care surgery
2025

Diaphragm dysfunction and interstitial lung disease in a preterm infant.

BMJ case reports
2025

Counting the Cost: The Hidden Financial Realities of Neuromuscular Disease Through Patient and Family Perspectives.

Health expectations : an international journal of public participation in health care and health policy
2025

Building capacity for patient-engagement in neuromuscular disease research: A network project.

Journal of neuromuscular diseases
2026

Aberrant Molecular Myelin Architecture in Charcot-Marie-Tooth Disease Type 1A and Hereditary Neuropathy With Liability to Pressure Palsies.

Glia
2026

A Psychometric Evaluation of Maximum Phonation Time and S/Z Ratio as Pragmatic Outcome Measures of Bulbar Function in Adults With Spinal Muscular Atrophy.

Muscle & nerve
2025

Establishing biomarkers and clinical endpoints in myotonic dystrophy type 1 (END-DM1): Protocol of an international natural history study.

PloS one
2025

Rethinking Pulmonary Function Tests in Patients with Neuromuscular Disease: The Potential Role of Electrical Impedance Tomography.

Journal of clinical medicine
2025

Dl-3-n-Butylphthalide Promotes Cortical Angiogenesis via Akt/GSK-3β Signaling in Ischemic Stroke Mice.

CNS neuroscience & therapeutics
2025

A novel mutation in FDX2 provides insights into the pathogenesis of MEOAL mitochondrial neuromuscular disease.

Cell death & disease
2025

U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictions.

Journal of neuromuscular diseases
2026

Intrathecal onasemnogene abeparvovec in treatment-naive patients with spinal muscular atrophy: a phase 3, randomized controlled trial.

Nature medicine
2025

Dantrolene-Responsive Muscle Stiffness in a Patient With a Normal Neurologic Exam and EMG: A Case Report.

Case reports in neurological medicine
2025

Comparative assessment of cough capacity in patients with neuromuscular disease: Spirometer versus portable peak flow meter.

Rehabilitacion
2026

A respiratory signature of disease progression in the Pompe rat.

Journal of neurophysiology
2025

Effects of a Coach-Guided Online Yogic Breathing Program on Quality of Life in People With Amyotrophic Lateral Sclerosis: A Mixed-Methods Pilot RCT.

The American journal of hospice & palliative care
2026

Profiling the TRPV4 ankyrin repeat domain interactome and its disruption by neuromuscular disease-causing mutations.

The Journal of biological chemistry
2025

Neuropalliative Care in Neuromuscular Disorders.

Continuum (Minneapolis, Minn.)
2025

Development and Feasibility Assessment of a Multimodal Digital Health Technology for Remote Monitoring of Symptoms in Myasthenia Gravis.

Digital biomarkers
2025

Non-invasive ventilation in pediatrics. A narrative review. Part 2: New and emerging modes of non-invasive ventilation.

Paediatric respiratory reviews
2025

Non-invasive ventilation in pediatrics: a narrative review. Part 1: conventional non-invasive ventilation.

Paediatric respiratory reviews
2025

Dystrophic Skeletal Muscle Phenotypes Can Be Horizontally Transferred via Fecal Microbiome Transplantations.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2025

[What can be learned from the new HAS AFM-Téléthon recommendations for clinical practice in musculoskeletal rehabilitation in neuromuscular pathologies?].

Medecine sciences : M/S
2026

Cellular immune endophenotypes separating early and late-onset myasthenia gravis.

JCI insight
2025

Neural Cues and Genomic Clues: NGS Insights into Neurogenic Sarcopenia and Muscle Atrophy.

International journal of molecular sciences
2025

Dystrophin-Deficient Muscular Dystrophy in a Family of Shiba Inu Dogs with a Complex Deletion Encompassing DMD Exon 5.

Genes
2025

Characterising PMP22-Proximal Partners in a Schwann Cell Model of Charcot-Marie-Tooth Disease Type1A.

Biology
2025

The enduring role of PCNL in complex stone disease: a systematic review of four challenging cohorts.

World journal of urology
2026

C-terminal extension of HSPB6 in a family with myopathy and cataract.

Human molecular genetics
2025

Obestatin treatment links mitochondrial homeostasis and skeletal muscle repair in Duchenne muscle dystrophy.

Molecular biomedicine
2025

CT-guided Lumbar Puncture for Intrathecal Nusinersen Injection in Patients with Spinal Muscular Atrophy: Technical Effectiveness, Safety, and Radiation Dose.

Clinical neuroradiology
2025

Diagnostic Performance of Three Serological Assays in Myasthenia Gravis: A Prospective Multicentre Study.

Scandinavian journal of immunology
2025

Not all Parkinsons patients with thoracolumbar spinal fusion are created equal: Highlighting the difference between long and short fusions.

North American Spine Society journal
2025

Muscle imaging of patients with RYR1-related myopathies and its significance to clinical features.

Neuromuscular disorders : NMD
2025

Methylprednisolone Restores Cognitive Impairment in mdx Mice by Inhibiting NF-κB/CCL5-mediated Neuroinflammation.

Molecular neurobiology
2026

Expanding the Genotype and Phenotype Diversity in a Chinese Cohort With TRPV4-Related Dysplasia.

Clinical genetics
2026

Building a Quantitative Telemedicine Platform for Myasthenia Gravis: Augmenting the Physical Examination.

Muscle & nerve
2025

Highlights of the Sleep and Breathing Conference 2025.

Breathe (Sheffield, England)
2025

Vesicocolic fistula in myasthenia gravis patient: A case report.

Medicine
2026

Impact of pneumothorax on clinical course of patients with amyotrophic lateral sclerosis on long-term ventilation.

Respiratory investigation
2026

Prevalence and Geographical Distribution of Patients With Congenital Myasthenic Syndromes in the United Kingdom.

Muscle & nerve
2025

Mifepristone alone and in combination with scAAV9-SMN1 gene therapy improves disease phenotypes in Smn2B/- spinal muscular atrophy mice.

Scientific reports
2025

A 12-Week Strength Training Improves Mitochondrial Respiration, H2O2 Emission and Skeletal Muscle Integrity in Women With Myotonic Dystrophy Type 1.

Acta physiologica (Oxford, England)
2025

Intrinsic dysfunction in muscle stem cells lacking dystrophin begins during secondary myogenesis.

Nature communications
2025

Does Isolated Ankle Arthrodesis Affect Medial Column Alignment in Patients With Progressive Collapsing Foot Deformity and End-stage Ankle Osteoarthritis?

Clinical orthopaedics and related research
2025

Novel missense variants associated with GNE myopathy.

Neuromuscular disorders : NMD
2025

The Neuromuscular Junction: A Shared Vulnerability in Aging and Disease.

The Journal of neuroscience : the official journal of the Society for Neuroscience
2025

MT-ATP6 variant as a cause of adult-onset hereditary spastic paraparesis: A case report and literature review.

Journal of neuromuscular diseases
2025

Post Extubation Noninvasive Respiratory Support for Pediatric ARDS.

Pediatric pulmonology
2025

Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerations.

Journal of neuromuscular diseases
2025

Natural history of patients with nonsense mutation Duchenne muscular dystrophy treated with ataluren in Spain.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2025

Myosin inhibition partially rescues the myofiber proteome in X-linked myotubular myopathy.

JCI insight
2025

Exploring the evidence for the use of protein biomarkers of muscular damage and disease progression in Duchenne and Becker muscular dystrophy: a systematic review and meta-analysis protocol.

BMJ open
2025

Psychometric Properties of MFM32 in Myotonic Dystrophy Type 1.

Archives of physical medicine and rehabilitation
2025

Reducing body myopathy due to a novel pathogenic variant in the FHL1 gene.

BMJ case reports
2025

Improved Lung Function with Home Oscillation and Lung Expansion Therapy in Children: A Case Series.

Pediatric allergy, immunology, and pulmonology
2026

Caregiver-reported Patient Experiences with Duchenne Muscular Dystrophy: Qualitative In-trial Interviews 1 Year After Delandistrogene Moxeparvovec in the Pivotal EMBARK Trial.

Neurology and therapy
2025

Globalizing newborn screening: bridging gaps in genetic diagnosis and treatment.

Frontiers in pediatrics
2025

Genetic and clinical landscape of Duchenne muscular dystrophy in Guatemala: insights from a national study.

Frontiers in genetics
2025

Early experience on omaveloxolone in adult patients with Friedreich's ataxia: a real-world observational study.

Journal of neurology
2026

Rehabilitation in Neuromuscular Diseases: Best Turkish Practice Recommendations by Multidisciplinary Experts.

Acta neurologica Belgica
2025

Compound Muscle Action Potential (CMAP) Amplitude Trajectories and Pattern in Adults with 5q-Spinal Muscular Atrophy Receiving Nusinersen Therapy: A Multicenter, Binational Observational Study.

European journal of neurology
2026

Diaphragm excursion as a predictor of noninvasive ventilation failure in the emergency department: A prospective study.

Heart & lung : the journal of critical care
2025

Abstracts from the MYO-MRI+ 2025 | Imaging in Neuromuscular Disease Conference.

Journal of neuromuscular diseases
2025

Dynamometric measurement of hand grip and pinch strength as functional independency outcome in neuromuscular diseases.

European journal of physical and rehabilitation medicine
2025

First Identification of CGG-Repeat Expansions in LRP12 in Korean Families With Oculopharyngodistal Myopathy Type 1.

Journal of clinical neurology (Seoul, Korea)
2025

Pediatric critical care admission after scoliosis surgery in children with underlying conditions: requirements, evolution and comparison with healthy children.

International journal of orthopaedic and trauma nursing
2025

Exploring the Trajectory of Swallowing Within Psychomotor Development in Spinal Muscular Atrophy: Moving Toward Integrated Care.

Audiology research
2025

Patterns of Adherence to Lung Volume Recruitment Therapy Amongst Individuals With Duchenne Muscular Dystrophy: A Secondary Analysis of the STEADFAST Randomized Controlled Trial.

Pediatric pulmonology
2025

Obstructive sleep apnea in community-dwelling polio survivors: a 5-year longitudinal follow-up study.

Frontiers in neurology
2025

Airway pressure release ventilation as a recruitment maneuver in mechanically ventilated children with restrictive lung disease.

Frontiers in pediatrics
2025

Gastrointestinal Dysautonomia: A Rare Immune-Related Adverse Event That Requires Early Recognition and High-Dose Immunosuppression.

Cureus
2025

Cost-Effectiveness Analysis of Efgartigimod vs Chronic Immunoglobulin for the Treatment of Myasthenia Gravis in Canada.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2025

Home Mechanical Ventilators: Indications for Use in Chronic Respiratory Failure.

Sleep medicine clinics
2025

Spinal muscular atrophy in India: Patient journey, access to care, treatment barriers, and strategic recommendations: Insights from experts.

Journal of neuromuscular diseases
2026

User experience and cybersickness in neuromuscular patients using recreational immersive virtual reality.

Disability and rehabilitation. Assistive technology
2025

Long-term neuromuscular, cardiac and liver outcomes in an adult man affected with Chanarin-Dorfman syndrome.

Molecular genetics and metabolism reports
2025

Drug Candidate BIO101 for Spinal Muscular Atrophy as Monotherapy or Combined With the Antisense Oligonucleotide ASO-10-27.

Journal of cachexia, sarcopenia and muscle
2025

A Family with Patients Manifesting Different Phenotypes of Neuromuscular Disease Depending on the CGG Repeat Number in LRP12.

Internal medicine (Tokyo, Japan)
2025

Conference proceedings from the Western Canadian Neuromuscular Conference (WCNMC) - September 27-29, 2024, Calgary, Canada.

Journal of neuromuscular diseases
2025

Parent and Clinician Perceptions of Suctioning in Hospitalized Children With Bronchiolitis.

Hospital pediatrics
2025

A qualitative, mixed-method approach to reaching consensus on function, fatigue, and fatigability outcomes in teens and adults living with spinal muscular atrophy.

Orphanet journal of rare diseases
2026

Wheelchair-assisted Ventilation in Neuromuscular Disease: The Abdominal Press-and-release Technique.

Archivos de bronconeumologia
2025

Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines.

Disease models & mechanisms
2025

Rescue therapy in myasthenia gravis.

International review of neurobiology
2025

Performing Compound Motor Action Potential Measurement in Zebrafish: A Description of Methodology and a Comparison Between Healthy and ALS-Affected Animals.

Muscle & nerve
2025

Statistical Shape Modeling Characterization of Cavovarus Deformity Between Demyelinating and Axonal Subtypes of Charcot-Marie-Tooth Disease.

Foot & ankle international
2025

Surface electrical impedance myography detects disease in an adult-onset SOD1-G93A zebrafish model of amyotrophic lateral sclerosis.

Scientific reports
2026

Machine learning prediction of multidrug-resistant urinary tract infections in brain and spinal cord injury patients: a dual-center validation study.

International journal of medical informatics
2025

Biallelic variants in ARHGAP19 cause a progressive inherited motor-predominant neuropathy.

The Journal of clinical investigation
2025

Transient imaging changes accompany 'spinal ICANS' following CAR T-cell therapy for large B-cell lymphoma in adults.

British journal of haematology
2025

Clinical characteristics and etiology-specific outcome in pediatric hypertrophic cardiomyopathy.

Clinical research in cardiology : official journal of the German Cardiac Society
2025

Positive airway pressure therapies improve sleep architecture in patients with chronic hypercapnic respiratory failure: A systematic review and meta-analysis.

Sleep medicine reviews
2025

Optimised machine learning for time-to-event prediction in healthcare applied to timing of gastrostomy in ALS: a multi-centre, retrospective model development and validation study.

EBioMedicine
2025

Clinical characteristics, cerebellar MR spectroscopy and response to 3,4-diaminopyridine in spinocerebellar ataxia 27B: the Sheffield Ataxia Centre experience.

Journal of neurology
2025

Indicators of different outcomes after prolonged weaning.

Scientific reports
2025

Enhanced proteasome activity in perifascicular myofibres is a hallmark of dermatomyositis and its inhibition is efficient in preclinical models.

Annals of the rheumatic diseases
2025

MiR-140-3p regulates axonal motor protein KIF5A and contributes to axonal transport degeneration in SMA.

Cell death discovery
Ver todos os 1.087 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença neuromuscular.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença neuromuscular

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.
    Annals of clinical and translational neurology· 2026· PMID 41853897mais citado
  2. Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.
    Molecular therapy : the journal of the American Society of Gene Therapy· 2026· PMID 41821312mais citado
  3. Expanding the phenotypic and immunological landscape of Alazami syndrome: Evidence from seven new patients with LARP7 gene variants.
    European journal of pediatrics· 2026· PMID 41811398mais citado
  4. Caring beyond the procedure: a qualitative study on thoracic surgery nurses' perspectives on chronic illness experiences of individuals with myasthenia gravis undergoing thymectomy.
    BMJ open· 2026· PMID 41802783mais citado
  5. Climate change and brain health, a risk management approach focusing on the European region: A narrative review.
    Journal of the neurological sciences· 2026· PMID 41780425mais citado
  6. Enabling equitable and inclusive travel experiences for dysphagia patients: a call to action for the aviation industry.
    Front Rehabil Sci· 2026· PMID 41994218recente
  7. Outpatient versus inpatient initiation of home mechanical ventilation in patients with amyotrophic lateral sclerosis - a protocol for a randomised trial.
    Dan Med J· 2026· PMID 41978444recente
  8. Preoxygenation When Standard Approaches Fail: Phenotype-Based Strategies for High-Risk Emergent Intubations.
    J Clin Med· 2026· PMID 41976778recente
  9. Pediatric HyperCKemia: a 13-year retrospective study and predictors of neuromuscular disease and metabolic myopathy.
    Eur J Pediatr· 2026· PMID 41961319recente
  10. Estimating health-state utility values for family-caregivers of patients with Duchenne muscular dystrophy using time trade-off valuation.
    J Patient Rep Outcomes· 2026· PMID 41961170recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:68381(Orphanet)
  2. MONDO:0019056(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q2246789(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença neuromuscular
Compêndio · Raras BR

Doença neuromuscular

ORPHA:68381 · MONDO:0019056
Ensaios
2 ativos
MedGen
UMLS
C0027868
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata